

## CURRICULUM VITAE

### SUSAN LINDA STRAMER

**PERMANENT MAILING ADDRESS** 15225 Dufief Dr.  
North Potomac MD 20878

**BIRTHDATE** May 20, 1953

#### EDUCATION

1975 Bachelor of Science  
Northern Illinois University  
DeKalb, IL 60115

1977 Master of Science  
Northern Illinois University  
DeKalb, IL 60115

1984 Doctor of Philosophy, Bacteriology  
University of Wisconsin  
Madison, WI 53706

#### CURRENT POSITION

American Red Cross

2014 to Present Vice President, Scientific Affairs, Biomedical Services, American Red Cross,  
Gaithersburg, MD  
NY State Laboratory Director in Diagnostic Immunology and Virology (including  
molecular diagnostics), American Red Cross Charlotte National Testing Laboratory

2004 – 2014 Executive Scientific Officer, Biomedical Services, American Red Cross,  
Gaithersburg, MD

1995 – 2003 Laboratory Director, National Confirmatory Testing Laboratory (NCTL),  
Gaithersburg, MD

#### POSITIONS AND HONORS

##### Professional Experience

1983-1986 Postdoctoral Fellow, Hepatitis Branch, Centers for Disease Control & Prevention, Atlanta,  
GA

1986-1994 Abbott Laboratories, Diagnostics Division  
Abbott Laboratories, Abbott Park, IL 60064  
Scientific Affairs Manager, Hepatitis/Retrovirus/Transfusion Sector; US Marketing  
Section Manager, Hepatitis/Retrovirus Research and Development and Technical Product  
Development

1995-present Member of the AABB Transfusion-Transmitted Diseases Committee

April 2017

1995-present	ARC liaison to the College of American Pathologists Transfusion Medicine Resources Committee
1999-2005	Member of the AABB Annual Meeting Planning Committee
2000-2005	Chair of the AABB Selection of Abstracts Committee for the Annual Meeting
2004-2005	Member of the AABB Governance Task Force
2004-2005	Member of the AABB Nominating Committee
2005-2014	Member of the AABB Board of Directors
2006-present	Member of the ISBT Working Party for Transfusion-Transmitted Infectious Diseases
2006-present	Member of the Hema-Quebec Safety Advisory Committee
2012-2013	President of AABB
2014-present	Chair of the AABB Transfusion-Transmitted Diseases Committee

### **Honors and Awards**

1999	Centers for Disease Control Charles C. Shepard Science Award
1999	American Statistical Association, Award for Outstanding Statistical Application
2002	American Red Cross Tiffany Award for Employee Excellence in Management
2003	American Red Cross Spirit of Excellence Award
2004	Centers for Disease Control Charles C. Shepard Science Award Nominee
2008	Centers for Disease Control Charles C. Shepard Science Award Nominee
2010	California Blood Bank Society Herb Perkins Scientific Award and Lectureship
2012	American Red Cross Tiffany Award for Employee Excellence in Mission Fulfillment
2012	American Red Cross President's Award for Employee Excellence in Management
2014	AABB Tibor Greenwalt Memorial Award and Lectureship
2015	NIH Richard J. Davey Award and Lectureship

## Professional Memberships

American Association of Blood Banks (AABB)

International Society for Blood Transfusion (ISBT)

## Publications

1. **Stramer SL.** Presumptive identification of *Klebsiella pneumoniae* on m-FC medium. Canadian Journal of Microbiology 1976;22:1774-6.
2. **Stramer SL, Starzyk MJ.** Improved growth of *Thermus aquaticus* on cellular lysates. Microbios 1978; 23:193-8.
3. **Stramer SL, Starzyk M.J.** The occurrence and survival of *Thermus aquaticus*. Microbios 1981;32:99-110.
4. **Stramer SL, Cliver DO.** Septage treatments to reduce the numbers of bacteria and polioviruses. Appl Environ Microbiol.1984;48:566-72.
5. **Stramer SL, Heller JS, Coombs RW, Ho DD, Allain JP.** Transmission of HIV by blood transfusion. N Engl J Med 1988;319:513-4.
6. Alhajjar BJ, **Stramer SL, Cliver DO, Harkin JM.** Transport modeling of biological tracers from septic systems. Water Research 1988;22:907-15.
7. Desai SM, Rupprecht KR, Casey JM, Aneja RA, Kramer DE, Braun DM, Gutierrez RA, Boardway K, **Stramer SL, Allen RG, Hampf H, Dawson GJ, Devare SG.** Genes of human immunodeficiency viruses, their expression in *Escherichia coli*, and their utility in diagnosis of viral infection. J. Cell. Biochem 1989;13B:268-72.
8. **Stramer SL, Heller JS, Coombs RW, Parry JV, Ho DD, Allain JP.** Markers of HIV infection prior to IgG antibody seropositivity. JAMA 1989;262:64-9.
9. Bloch AB, **Stramer SL, Smith JD, Margolis HS, Fields HA, Gerba CP, McKinley TW, Maynard JE, Sikes RK.** Recovery of hepatitis A virus from a water supply responsible for a common source outbreak of hepatitis A. AJP 1990;80:428-430.
10. Ayres L, Avillez F, Garcia-Benito A, Deinhardt F, Gurtler L, Denis F, Leonard G, Ranger S, Grob P, Joller-Jemelka H, Hess G, Seidl SS, Flacke H, Simon F, Brun-Vezinet F, Sondag D, Andre A, Hampf H, Schoen R, **Stramer SL, Troonen H.** Multicenter evaluation of a new recombinant enzyme immunoassay for the combined detection of antibody to HIV-1 and HIV-2. AIDS 1990;4:131-8.
11. Jackson JB, MacDonald KL, Cadwell J, Sullivan C, Kline WE, Hanson M, Sannerud KJ, **Stramer SL, N.J. Fildes NJ, S.Y. Kwok SY, J.J. Sninsky JJ, R.J. Bowman RJ, H.F. Polesky HF, Balfour HH, Osterholm MT.** Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1. N Engl J Med 1990;322:217-22.
12. Gallarda JL, Henrard DR, Liu D, Harrington S, **Stramer SL, Valinsky JE, Wu P.** Early detection of antibody to human immunodeficiency virus type 1 by using an antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody. Journal of Clinical Microbiology 1992; 30:2379-84.
13. Fitzgibbons D, Barriga G, Seymour E, **Stramer SL.** HIV antibody EIA and western blot assay results on paired serum and saliva specimens. Annals of the New York Academy of Sciences 1993;694:314-6.

14. Grant RM, Piwowar EM, Mbidde EK, Muzawalu W, Rugera S, J. Abima J, **Stramer SL**, Kataaha P, Jackson B. Comparison of saliva and serum for human immunodeficiency virus type 1 antibody testing in Uganda using a rapid recombinant assay. *Clinical and Diag. Laboratory Immunology* 1996;1071-412x/96:640-4.
15. Janssen RS, Satten GA, **Stramer SL**, Rawal BD, O'Brien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. *JAMA* 1998;280:42-8.
16. Busch MP, **Stramer SL**. The efficiency of HIV p24 antigen screening of US blood donors: projections versus reality. *Infusion Therapy and Transfusion Medicine* 1998;25:194-7.
17. Sullivan MT, Guido EA, Metler RP, Schable CA, Williams AE, **Stramer SL**. Identification and characterization of an HIV-2 antibody-positive blood donor in the United States. *Transfusion* 1998; 38:189-93.
18. McCullough J, Bianco C, Busch M, Dodd R, Hewlett IK, Jackson JB, Katz LM, McFarland J, Mied PA, Page P, Preston MS, Simon T, **Stramer SL**, Stroncek D, Young CT. Interagency Genome Amplification Testing Task Force: preliminary report. *Transfusion* 1998;38:903-4.
19. Lui H, Shah M, **Stramer SL**, Chen W, Weiblen BJ, Murphy EL. Sensitivity and specificity of human T-lymphotropic virus (HTLV) types I and II polymerase chain reaction and several serologic assays in screening a population with high prevalence of HTLV-II. *Transfusion* 1999;39:1185-93.
20. Dodd RY, **Stramer SL**. Indeterminate results in blood donor testing: What you don't know can hurt you. *Transfusion Medicine Reviews* 2000;14:151-60.
21. Busch MP, Kleinman SH, Jackson B, **Stramer SL**, Hewlett I, McCullough J. for the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases. *Transfusion* 2000;40:143-59.
22. Tobler LH, Tegtmeier G, **Stramer SL**, Quan S, Dockter J, Giachetti G, Busch MP. Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays: justification and rational implementation. *Transfusion* 2000;40:15-24.
23. Tobler LH, Lee SR, **Stramer SL**, Peterson J, Kochesky R, Watanabe K, Quan S, Polito A, Busch MP. Performance of second- and third-generation RIBA for confirmation of third-generation HCV EIA-reactive blood donations. *Transfusion* 2000;40:917-23.
24. **Stramer SL**, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. *Transfusion* 2000;40:1165-8.
25. Peoples BG, Preston SB, Tzeng JL, **Stramer SL**, Gifford L, Wissel ME. Prolonged antibody-negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient. *Transfusion* 2000; 40:1280-1.
26. **Stramer SL**. Nucleic acid testing for transfusion-transmissible agents. *Current Opinion in Hematology* 2000;7:387-91.
27. Dodd RY, **Stramer SL**, Aberle-Grasse J, Notari E. Risk of hepatitis and retroviral infections among blood donors and introduction of nucleic acid testing (NAT). *Developmental Biological Standards* 2000; 102:19-27.
28. Tobler LH, **Stramer SL**, Kleinman SH, Brodsky JP, Todd DS, Busch MP. Misclassification of HCV-

viremic blood donors as indeterminate by RIBA 3.0 because of human superoxide dismutase reactivity. *Transfusion* 2001;41:1625-6.

29. Lelie PN, van Drimmelen HAJ, Cuypers HTM, Best SJ, **Stramer SL**, Hyland C, Allain JP, Moncharmont P, Defer C, Nübling M, Glauser A, Cardoso MDS, Viret JF, Lankinen MH, Grillner L, Wirthmüller U, Coste J, Schottstedt V, Masecar B, Dax EM. Sensitivity of HCV RNA and HIV RNA blood screening assays. *Transfusion* 2002;42:527-36.
30. Vargo J, Smith K, Knott C, Wang S, Fang C, McDonough S, Giachetti C, Caglioti S, Gammon R, Gilbert D, Jackson JB, Richards W, **Stramer SL**, Mimms L. Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. *Transfusion* 2002;42:876-85.
31. Dodd RY, Notari EP IV, **Stramer SL**. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. *Transfusion* 2002;42:975-9.
32. **Stramer SL**. NAT update: where are we today? *Advances in Transfusion Safety*. Dev Biol. Basel, Karger 2002;108:41-56.
33. **Stramer SL**. US NAT yield: where are we after 2 years? *Transfusion Medicine* 2002;12:243-53.
34. Dodd RY, Orton SL, Notari EP IV, **Stramer SL**. Viral marker rates among blood donors before and after the terrorist attacks on the United States on September 11, 2001. *Transfusion* 2002;42:1240-1.
35. Tobler LH, Dockter J, **Stramer SL**, Kleinman SH, Todd D, Giachetti C, Busch MP. Use of Procleix HIV-1 and HCV discriminatory assays to detect HIV and HCV RNA in whole blood. *Transfusion* 2002;42:1525-7.
36. Sharma U, **Stramer SL**, Wright DJ, Glynn S, Hermansen S, Schreiber G, Kleinman S, Busch MP. Impact of changes in viral marker screening assays. *Transfusion* 2003;43:202-14.
37. Jackson BR, Busch MP, **Stramer SL**, Aubuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. *Transfusion* 2003;43:721-9.
38. Beltrami EM, Kozak A, Williams IT, Saekhou AM, Kalish ML, Nainan OV, **Stramer SL**, Fucci MH, Frederickson D, Cardo DM. Transmission of HIV and hepatitis C virus from a nursing home patient to a health care worker. *American Journal of Infection Control* 2003;31:168-75.
39. Tobler LH, **Stramer SL**, Lee SR, Masecar BL, Peterson JE, Davis EA, Andrews WE, Brodsky JP, Kleinman SH, Phelps BH, Busch MP. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening. *Transfusion* 2003;43:1452-9.
40. Chudy M, Hewlett I, Saldanha J, Bianco C, Conrad AJ, Gierman T, Heldebrant C, Rautmann GG, Roth WK, **Stramer SL**, Weimer T, Whitaker B, Zerlauth G. Technical considerations for the performance of nucleic acid amplification technology (NAT) The NAT Task Force Group. *Biologicals* 2003;31:153-9.
41. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, **Stramer SL**, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME for the West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. *N Engl J Med* 2003;349:1236-45.
42. Orton SL, **Stramer SL**, Dodd RY, Alter MJ. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. *Transfusion* 2004;44:275-81.
43. **Stramer SL**, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP.

Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. *N Engl J Med* 2004;351:760-8.

44. Zou S, Dodd RY, **Stramer SL**, Strong DM. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. *N Engl J Med* 2004;351:751-9. Zou S, Notari EP, **Stramer SL**, Wajab F, Musavi F, Dodd RY. Patterns of age-and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. *Transfusion* 2004;44:1640-7.
45. **Stramer SL**. Viral diagnostics in the arena of blood donor screening. *Vox Sanguinis* 2004;87(Suppl 2):180-3.
46. Macedo de Oliveira A, Beecham BD, Montgomery SP, Lanciotti RS, Linnen JM, Giachetti C, Pietrelli LA, **Stramer SL**, Safranek TJ. West Nile virus blood transfusion-related infection despite nucleic acid testing. *Transfusion* 2004;44:1695-9.
47. Strong DM, Nelson K, Pierce M, **Stramer SL**. Preventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid. *Cell and Tissue Banking* 2005;6:255-62.
48. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby DA, Lin L, **Stramer SL**. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. *Transfusion Medicine Reviews* 2005;19:110-26.
49. Busch MP, Glynn SA, **Stramer SL**, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. *Transfusion* 2005;45:254-64.
50. **Stramer SL**. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. Editorial *Transfusion* 2005;45:1242-6.
51. **Stramer SL**, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile virus among blood donors in the United States, 2003 and 2004. *N Engl J Med* 2005;353:451-9.
52. Prince HE, Tobler LH, Lapé-Nixon M, Foster GA, **Stramer SL**, Busch MP. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. *Journal of Clinical Microbiology* 2005;43:4316-20.
53. Prince HE, Lapé-Nixon M, Busch MP, Tobler LH, Foster GA, **Stramer SL**. Utilization of follow-up specimens from viremic blood donors to assess the value of West Nile virus immunoglobulin G avidity as an indicator of recent infection. *Clinical and Diagnostic Laboratory Immunology* 2005;12:1123-6.
54. Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, Cuijpers HT, Elgin R, Ekermo B, Epstein JS, Flesland O, Heier HE, Henn G, Hernandez JM, Hewlett IK, Hyland C, Keller AJ, Krusius T, Levičnik-Stezina S, Levy G, Lin CK, Margaritis AR, Muylle L, Neiderhauser C, Pastila S, Pillonel J, Pineau J, van de Poel CL, Politis C, Roth WK, Sauleda S, Seed CR, Sondag-Thull D, **Stramer SL**, Strong M, Vamvakas EC, Velati C, Vesga MA, Zanetti A. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. *Vox Sanguinis* 2005;88:289-303.
55. Tobler LH, **Stramer SL**, Lee SR, Bagget D, Wright D, Hirschhorn D, Walsh I, Busch MP. Performance of ORTHO HCV core antigen and trak-C assays for detection of viraemia in pre-seroconversion plasma and whole blood donors. *Vox Sanguinis* 2005;89:201-7.

56. Busch MP, Wright DJ, Tobler LH, **Stramer SL**, Kleinman SH, Prince HE, Bianco C, Foster GA, Peterson LR, Nemo G, Glynn SA. West Nile virus infections projected from blood donor screening data, United States, 2003. *Emerging Infectious Diseases* 2006;12:395-402.
57. Orton SL, **Stramer SL**, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. *Transfusion* 2006;46:272-7.
58. Busch MP, Glynn SA, **Stramer SL**, Orland J, Murphy EL, Wright DJ, Kleinman S. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. *Transfusion* 2006; 46:469-75.
59. Kleinman SH, **Stramer SL**, Brodsky JP, Caglioti S, Busch MP. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms. *Transfusion* 2006;46:695-702.
60. **Stramer SL**, Foster GA, Dodd RY. Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and – II confirmatory algorithm, 1999 to 2004. *Transfusion* 2006;46:703-7.
61. **Stramer SL**, Custer B, Busch MP, Dodd RY. Strategies for testing blood donors for West Nile virus. *Transfusion* 2006;46:2036-7.
62. Tobler LH, **Stramer SL**, Chien DY, Lin S, Arcangel P, Phelps BH, Cooper SL, Busch MP. Antibodies to a novel antigen in acute hepatitis C virus infections. *Vox Sanguinis* 2007; 92:1-7.
63. Alter HJ, **Stramer SL**, Dodd RY. Emerging infectious diseases that threaten the blood supply. *Seminars in Hematology* 2007;44:32-41.
64. **Stramer SL**. Reacting to an emerging safety threat: West Nile virus in North America. *Dev Biol (Basel)* 2007;127:43-58.
65. **Stramer SL**. Current risks of transfusion-transmitted agents: a review. *Archives of Pathology and Laboratory Medicine* 2007;131:702-7.
66. Herring BL, Bernardin F, Caglioti S, **Stramer SL**, Tobler L, Andrews W, Cheng L, Rampersad S, Cameron C, Saldanha J, Busch MP, Delwart E. Phylogenetic analysis of WNV in North American blood donors during the 2003-2004 epidemic seasons. *Virology* 2007;363:220-8.
67. Bernardin F, **Stramer SL**, Reherrmann B, Page-Shafer K, Cooper S, Bangsberg DR, Hahn J, Tobler L, Busch MP, Delwart E. High levels of subgenomic HCV plasma RNA in immunosilent infections. *Virology* 2007;365:446-56.
68. Rios M, Daniel S, Chancey C, Hewlett IK, **Stramer SL**. West Nile virus adheres to human red blood cells in whole blood. *Clinical Infectious Diseases* 2007;45:181-6.
69. Klimashevskaya S, Obriadina A, Ulanova T, Bochkova G, Burkov A, Araujo A, **Stramer SL**, Tobler LH, Busch MP, Fields HA. Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index. *Journal of Clinical Microbiology* 2007;45:3400-3.
70. Tang S, Zhao J, Storhoff JJ, Norris PJ, Little RF, Yarchoan R, **Stramer SL**, Patno T, Domanus M, Dhar A, Mirkin CA, Hewlett IK. Nanoparticle-based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen. *Journal of Acquired Immune Deficiency Syndrome* 2007;46:231-7.

71. Benjamin RJ, Busch MP, Fang CT, Notari EP, Puren A, Schoub BD, Tobler LH, Hogrefe W, Heyns ADP, **Stramer SL**, Crookes RL. Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. *Transfusion* 2008;48:295-303.
72. Grinev A, Daniel S, **Stramer SL**, Rossmann S, Caglioti S, Rios M. Genetic variability of West Nile virus in US blood donors, 2002-2005. *Emerging Infectious Diseases* 2008;14:436-44.
73. Reesink HW, Engelfriet CP, Hyland CA, Coghlan P, Tait B, Wsolak M, Keller AJ, Henn G, Mayr WR, Thomas I, Osselaer JC, Lambermont M, Beaten M, Wendel S, Oiu Y, Georgsen J, Krusius T, Mäki T, Andreu G, Morel P, Lefrère JJ, Rebullà P, Giovanelli S, Butti B, Lecchi L, Mozzi F, van Hilten JA, Zwaginga JJ, Flanagan P, Flesland Ø, Brojer E, Łętowska M, Åkerblom O, Norda R, Prowse C, Dow B, Jarvis L, Davidson F, Kleinman S, Bianco C, **Stramer SL**. Biobanks of blood from donors and recipients of blood products. *Vox Sanguinis* 2008;94:242-60.
74. Reesink HW, Engelfriet CP, Henn G, Mayr WR, Delage G, Bernier F, Krusius T, Assal A, Gallian P, Corbi C, Morel P, David B, De Micco P, Murokawa H, Yugi H, Hino S, Tadokoro K, Flesland Ø, Brojer E, Łętowska M, Olim G, Nascimento F, Gonçalves H, Castro L, Morais M, Stezinar SL, Alvarez M, Sauleda S, González R, Niederhauser C, Stolz M, Allain JP, Owusu-Ofori S, Eglin R, **Stramer SL**, Busch M, Strong DM, Epstein J, Biswas R. Occult hepatitis B infection in blood donors. *Vox Sanguinis* 2008;94:153-66.
75. Rondini S, Pingle MR, Das S, Tesh R, Rundell MS, Home J, **Stramer SL**, Turner K, Rossmann SN, Lanciotti R, Spier EG, Muñoz-Jordán J, Larone D, Spitzer E, Barany F, Golightly LM. Development of multiplex PCR-ligase detection reaction assay for detection of West Nile virus. *Journal of Clinical Microbiology* 2008;46:2269-79.
76. Mohammed H, Linnen JM, Muñoz-Jordán JL, Tomashek K, Foster GA, Broulik AS, Petersen L, **Stramer SL**. Dengue virus in blood donations, Puerto Rico, 2005. *Transfusion* 2008;48:1348-54.
77. Bern C, Montgomery SP, Katz L, Caglioti S, **Stramer SL**. Chagas disease and the US blood supply. *Current Opinions in Infectious Disease* 2008;21:476-82.
78. Katz L, Strong DM, Tegtmeier G, **Stramer SL**. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen. *Transfusion* 2008;48:2315-22.
79. Rios M, Daniel S, Dayton AI, Wood O, Hewlett IK, Epstein JS, Caglioti S, **Stramer SL**. *In vitro* evaluation of the protective role of human antibodies to West Nile virus (WNV) produced during natural WNV infection. *Journal of Infectious Diseases* 2008;198:1300-8.
80. Allain JP, **Stramer SL**, Carneiro-Proietti ABF, Martins ML, Lopes da Silva SN, Ribeiro M, Proietti FA, Reesink HW. Transfusion-transmitted infectious diseases. *Biologicals* 2009; 37:71-7.
81. Brennan CA, **Stramer SL**, Holzmayer V, Yamaguchi J, Foster GA, Notari EP, Schochetman G, Devare SG. Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. *Transfusion* 2009;49:125-33.
82. Hatano H, Delwart EL, Norris PJ, Lee TH, Williams JD, Hunt PW, Hoh R, **Stramer SL**, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. *Journal of Virology* 2009;83:329-35.
83. Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof DE, Follmann D, **Stramer SL**, Margolis LB, Murphy PM. Genetic variation in OAS1 is a risk



factor for initial infection with West Nile Virus in man. *PLoS Pathogens* 2009;5:1-12.

84. Zou S, Notari EP, Fang CT, **Stramer SL**, Dodd RY. Current value of serologic test for syphilis as a surrogate marker for blood-borne viral infections among blood donors in the United States. *Transfusion* 2009;49:655-61.
85. Anderson SA, Yang H, Gallagher LM, O'Callaghan S, Forshee RA, Busch MP, McKenna MT, Williams I, Williams A, Kuehnert MJ, **Stramer SL**, Kleinman S, Epstein J, Dayton AI. Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. *Transfusion* 2009;49:1102-14.
86. Zou S, **Stramer SL**, Notari EP, Kuhns MC, Krysztof DE, Musavi F, Fang CT, Dodd RY. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. *Transfusion* 2009;49:1609-20.
87. Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof DE, Follmann D, **Stramer SL**, Murphy PM. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. *Journal of Infectious Diseases* 2010;201:178-85.
88. Petersen LR, **Stramer SL**, Powers AM. Chikungunya virus: possible impact on transfusion medicine. *Transfusion Medicine Reviews* 2010;24:15-21.
89. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, **Stramer SL**. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. *Transfusion* 2010;50:1495-1504.
90. Zou S, Musavi F, Notari EP, **Stramer SL**, Dodd RY. Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008. *Transfusion* 2010;50:1487-94.
91. Tang S, Zhao J, Wang A, Viswanath R, Harma H, Little RF, Yarchoan R, **Stramer SL**, Nyambi PN, Lee S, Wood O, Wong EY, Wang X, Hewlett IK. Characterization of immune responses to capsid protein (p24) of human immunodeficiency virus type 1: implications for detection. *Clinical Vaccine Immunology* 2010;17:1244-51.
92. Zou S, Foster GA, Dodd RY, Petersen LR, **Stramer SL**. West Nile fever characteristics among viremic persons identified through blood donor screening. *Journal of Infectious Diseases* 2010;202(9):1354-61.
93. Brennan CA, Yamaguchi J, Devare SG, Foster GA, **Stramer SL**. Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007. *Transfusion* 2010;50:2707-12.
94. **Stramer SL**, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W. Nucleic acid testing to detect HBV infection in blood donors. *N Engl J Med* 2011;364:236-47.
95. Klein HG, Dodd RY, Hollinger FB, Katz LM, Kleinman S, McCleary KK, Silverman RH, **Stramer SL**. for the AABB Interorganizational Task Force on XMRV. Xenotropic murine leukemia virus-related virus (XMRV) and blood transfusion: report of the AABB Interorganizational XMRV Task Force. *Transfusion* 2011;51:654-61.
96. **Stramer SL**, Notari EP, Zou S, Krysztof DE, Brodsky JP, Tegtmeier GE, Dodd RY. Human T-lymphotropic virus antibody screening of blood donors: rates of false-positive results and evaluation of a potential donor reentry algorithm. *Transfusion* 2011;51:692-701.

97. Meny GM, Santos-Zabala L, Szallasi A, **Stramer SL**. West Nile virus infection transmitted by granulocyte transfusion. *Blood* 2011;117:5778-9.
98. Atreya C, Nakhasi H, Mied P, Epstein J, Hughes J, Gwinn M, Kleinman S, Dodd R, **Stramer SL**, Walderhaug M, Ganz P, Goodrich R, Tibbetts C, Asher D. FDA Workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety. *Transfusion* 2011; 51:1855-71.
99. **Stramer SL**, Krysztof DE, Brodsky JP, Fickett TA, Reynolds B, Phikulsod S, Oota S, Lin M, Saldanha J, Kleinman SH. Sensitivity comparison to two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield. *Transfusion* 2011;51:2012-22.
100. Kassanjee R, Welte A, McWalter TA, Keating SM, Vermeulen M, **Stramer SL**, Busch MP. Seroconverting blood donors as a resource for characterizing and optimizing recent infection testing algorithms for incidence estimation. *PLoS ONE* 2011;6(6):e20027:1-8.
101. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukić I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren, M. Naukkarinen, A. Assal, C. Jork, M.K. Hourfar, P.Michel, R. Offergeld, L. Pichl, M. Schmidt, V. Schottstedt J, Seifried E, Wagner F, Weber-Schehl M, Politis C, Lin C, O’Riordan J, Gottreich A, Shinar E, Yahalom V, Velati C, Satake M, Sanad N, Sisene I, Bon AH, Koppelman M, Flanagan P, Flesland O, Brojer, M. Łętowska, F. Nascimento, E. Zhiburt, S.S. Chua, D. Teo, S. Levicnik Stezinar, M. Vermeulen, R. Reddy E, Park Q, Castro E, Eiras A, Gonzales Fraile I, Torres P, Ekermo B, Niederhauser C, Chen H, Oota S, Brant LJ, Eglin R, Jarvis L, Mohabir L, Brodsky J, Foster GA, Jennings C, Notari EP, **Stramer SL**, Kessler D, Hillyer C, Kamel H, Katz L, Taylor C, Panzer S, Reesink HW. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. *Vox Sanguinis* 2012;102:82-90.
102. Karafin MS, **Stramer SL**. The scientific method at work: xenotropic murine leukemia virus-related virus is neither a cause of chronic fatigue syndrome nor a threat to the blood supply. *Transfusion* 2012; 52:222-5.
103. Dodd RY, Hackett Jr. JR, Linnen JM, Dorsey K, Wu Y, Zou S, Qiu X, Swanson PA, Schochetman G, Gao K, Carrick JM, Krysztof DE, **Stramer SL**. Xenotropic murine leukemia virus-related virus does not pose a risk to blood recipient safety. *Transfusion* 2012;52:298-306.
104. **Stramer SL**, Zou S, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? *Transfusion* 2012; 52:440-6.
105. Xie SR, Bish DR, Bish EK, Slonim AD, **Stramer SL**. Safety and waste considerations in donated blood screening. *European Journal of Operational Research* 2012;217(3):619-32.
106. Zou S, **Stramer SL**, Dodd RY. Donor testing and risk: Current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. *Transfusion Medicine Reviews* 2012; 26:119-28.
107. Delwart E, Slikas E, **Stramer SL**, Kamel H, Kessler D, Krysztof DE, Tobler LH, Carrick DM, Steele WR, Todd D, Wright DJ, Kleinman SH, Busch MP. for the NHLBI-REDS-II Study Group. Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. *Journal of Infectious Diseases* 2012;205(6):875-85.
108. **Stramer SL**, Collins C, Nugent T, Wang X, Fuschino M, Heitman JW, Law J, Krysztof DE, Kiely N,

- Todd D, Vermeulen NMJ, Harrington K, Kamel H, Kelvin DJ, Busch MP, St. George K, Hewlett IK, Linnen JM, Norris PJ. For the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Sensitive detection assays for influenza RNA do not reveal viremia in US blood donors. *Journal of Infectious Diseases* 2012;205(6):886-94.
109. Manak M, Sina S, Anekella B, Hewlett I, Sanders-Buell E, Ragupathy V, Kim J, Vermeulen M, **Stramer SL**, Sabino E, Grabarczyk P, Michael N, Peel S, Garrett P, Tovanabutra S, Busch MP, Schito M. Pilot studies for development of an HIV subtype panel for surveillance of global diversity. *AIDS Research and Human Retroviruses*. 2012;28(6):594-606.
  110. Martin LA, **Stramer SL**, Kuhns MC, Schlauder GG. Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations. *Transfusion* 2012; 52:2201-8.
  111. Pybus OG, Suchard MA, Lemey P, Bernardin FJ, Rambaut A, Crawford FW, Gray RR, Arinaminpathy N, **Stramer SL**, Busch MP, Delwart EL. Unifying the spatial epidemiology and molecular evolution of emerging epidemics. *PNAS* 2012;109(37)15066-71.
  112. Mohammed H, Tomashek KM, **Stramer SL**, Hunsperger E. Prevalence of anti-dengue immunoglobulin G antibodies among American Red Cross blood donors in Puerto Rico, 2006. *Transfusion* 2012;52:1652-56.
  113. **Stramer SL**, Linnen JM, Carrick JM, Foster GA, Krysztof DE, Zou S, Dodd RY, Tirado-Marrero LM, Hunsperger E, Santiago GA, Muñoz-Jordán JL, Tomashek KM. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. *Transfusion* 2012;52:1657-66.
  114. Benjamin RJ, **Stramer SL**, Leiby DA, Dodd RY, Fearon M, Castro E. *Trypanosoma cruzi* infection in North America and Spain: evidence in support of transfusion transmission. *Transfusion* 2012;52:1913-21.
  115. Cantey PT, **Stramer SL**, Townsend RL, Kamel H, Ofafa K, Todd CW, Currier M, Hand S, Varnado W, Dotson E, Hall C, Jett PL, Montgomery SP. The United States *Trypanosoma cruzi* Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. *Transfusion* 2012;52:1922-30.
  116. Keating SM, Hanson D, Lebedeva M, Laeyendecker O, Ali-Napo NL, Owen SM, **Stramer SL**, Moore RD, Norris PJ, Busch MP. Lower- sensitivity and avidity modifications of the VITROS Anti-HIV1+2 assay for detection of recent HIV infections and incidence estimation. *J. Clin. Microbiol.* 2012;50:12 3968-76.
  117. Añez G, Heisey DA, Espina LM, **Stramer SL**, Rios M. Phylogenetic analysis of dengue virus types 1 and 4 circulating in Puerto Rico and Key West, Florida, during 2010 epidemics. *Am J Trop Med Hyg* 2012;87:548-53.
  118. Glynn SA, Busch MP, Dodd RY, Katz LM, **Stramer SL**, Klein HG, Simmons G, Kleinman SH, Shurin SB. for the NHLBI Emerging Infectious Disease Task Force convened November 7, 2011. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. *Transfusion* 2013;53:438-54.
  119. Gallagher LM, Ganz PR, Yang H, Kessler DA, O'Brien SF, Custer BS, Busch MP, Dodd RY, **Stramer SL**, Walderhaug MO, Forshee RA, Williams AE, Espstein JS, Anderson SA. Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop. *Transfusion* 2013;53:455-63.

120. O'Connell RJ, Gates RG, Bautista CT, Imbach M, Eggleston JC, Beardsley SG, Manak MM, Gonzales R, Rentas FJ, Macdonald VW, Cardo LJ, Reiber DT, **Stramer SL**, Michael NL, Peel SA. Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings. *Transfusion* 2013;53:505-17.
121. Añez G, Grinev A, Chancey C, Ball C, Akolkar N, Land KJ, Winkelman V, **Stramer SL**, Kramer LD, Rios M. Evolutionary dynamics of west nile virus in the United States, 1999-2011: phylogeny, selection pressure and evolutionary time-scale analysis. *PLoS Negl Trop Dis.* 2013;7(5):e2445.
122. Sabino EC, Lee TH, Montalvo L, Nguyen ML, Leiby DA, Carrick DM, Otani MM, Vinelli E, Wright D, **Stramer SL**, Busch M. For the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II) International Program. Antibody levels correlate with detection of *Trypanosoma cruzi* DNA by sensitive polymerase chain reaction assays in seropositive blood donors and possible resolution of infection over time. *Transfusion* 2013;53:1257-65.
123. Dorsey KA, Moritz ED, Steele WR, Eder AF, **Stramer SL**. A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010. *Transfusion* 2013;53:1250-6.
124. **Stramer SL**, Dodd RY, Brodsky JP. The value of screening signal-to-cutoff ratios for hepatitis C virus antibody confirmation. *Transfusion* 2013;53:1497-1500.
125. **Stramer SL**, Dodd, RY. for the AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. *Transfusion* 2013;53:2375-83.
126. **Stramer SL**, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? *Transfusion* 2013;53:2449-58.
127. **Stramer SL**, Krysztof DE, Brodsky JP, Fickett TA, Reynolds B, Dodd RY, Kleinman SH. Comparative analysis of triplex nucleic acid test assays in United States blood donors. *Transfusion* 2013;53:2525-37.
128. Keating SM, Heitman JD, Wu S, Deng X, **Stramer SL**, Kuhns MC, Mullen C, Norris PJ, Busch MP. Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. *J Infectious Dis.* 2013:1-10.
129. Grinev A, Chancey C, Germán A, Ball C, Winkelman V, Williamson P, Foster GA, **Stramer SL**, Rios M. Genetic analysis of West Nile virus isolates from an outbreak in Idaho, United States, 2006-2007. *Int. J. Environ. Res. Public Health* 2013;10:4486-4506.
130. Jackson BR, Kucerova Z, Roy SL, Aguirre G, Weiss J, Sriram R, Yoder J, Foelber R, Baty S, Derado G, **Stramer SL**, Winkelman V, Visvesvara GS. Serologic survey for exposure following fatal *Balamuthia mandrillaris* infection. *Parasitol Res* 2014;113:1305-11.
131. Bish EK, Ragavan PK, Bish DR, Slonim AD, **Stramer SL**. A probabilistic method for the estimation of residual risk in donated blood. *Biostatistics* 2014;1-16.
132. **Stramer SL**. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. *ISBT Science Series* 2014;9:30-6.
133. Steele WR, Hewitt EH, Kaldun AM, Krysztof DE, Dodd RY, **Stramer SL**. Donors deferred for self-reported Chagas disease history: does it reduce risk? *Transfusion* 2014;54:2092-97.
134. Moritz ED, Winton CS, Johnson ST, Krysztof DE, Townsend RL, Foster GA, Devine P, Molloy P,

- Brissette E, Berardi VP, **Stramer SL**. Investigational screening for *Babesia microti* in a large repository of blood donor samples from nonendemic and endemic areas of the United States. *Transfusion* 2014; 54:2226-36.
135. Enjalbert F, Krysztof DE, Candotti D, Allain JP, **Stramer SL**. Comparison of seven hepatitis B virus (HBV) nucleic acid testing assays in selected samples with discrepant HBV marker results from United States blood donors. *Transfusion* 2014;54:2485-95.
  136. Bish DR, Bish EK, Xie SR, **Stramer SL**. Going beyond same-for-all testing of infectious agents in donated blood. *IIE Transactions* 2014;46:1147-68.
  137. Townsend RL, Mortiz ED, Fialkow LB, Berardi V, **Stramer SL**. Probable transfusion-transmission of *Anaplasma phagocytophilum* by leukoreduced platelets. *Transfusion* 2014;54:2828-32.
  138. Snyder EL, **Stramer SL**, Benjamin RJ. The safety of the blood supply – time to raise the bar. *N Engl J Med* 2015;372:1882-5.
  139. Dodd RY, Foster GA, **Stramer SL**. Keeping blood transfusion safe from West Nile virus: American Red Cross experience, 2003-2012. *Transfusion Medicine Reviews* 2015;29:153-61.
  140. Custer B, Kessler D, Vahidnia F, Leparo G, Krysztof DE, Shaz B, Kamel H, Glynn S, Dodd RY, **Stramer SL**. For the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II) Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. *Transfusion* 2014;55:1098-107.
  141. Shields K, Cumming M, Rios J, Wong MT, Zwicker JI, **Stramer SL**, Alonso CD. Transfusion-associated *Anaplasma phagocytophilum* infection in a pregnant patient with thalassemia trait: a case report. *Transfusion* 2014;55:719-25.
  142. Moorman AC, **Stramer SL**, Schaefer MK, Collier MG, Suryaprasad A, Kuehnert MJ, Moore Z, Rowan E, Habicht K, Bradley K, Fucci MC, Hopkins C, Xu F. Incident hepatitis among repeat blood donors: a sentinel event signaling possible health care-associated infection and need for reporting to public health authorities. *Transfusion* 2015;55:2531-3.
  143. Bish EK, Moritz ED, El-Amine H, Bish DR, **Stramer SL**. Cost-effectiveness of *Babesia microti* antibody and nucleic acid blood donation screening results from prospective investigational studies. *Transfusion* 2015;55:2256-71.
  144. Moritz ED, **Stramer SL**. Blood donation screening for *Babesia microti*: feasibility and results. *ISBT Science Series* 2015;10(Suppl 1):169-172.
  145. **Stramer SL**, Dodd Ry, Chiu CY. Advances in testing technology to ensure transfusion safety – NAT and beyond. *ISBT Science Series*; 10(Suppl 1):55-64.
  146. Laperche S, Nübling CM, **Stramer SL**, Brojer E, Grabarczyk P, Yoshizawa H, Kalibatas V, El Elkyabi M, Moftah F, Girault A, van Drimmelen H, Busch MP, Lelie N. Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples. *Transfusion* 2015;55:2489-98.
  147. Chiu CY, Bres V, Yu G, Krysztof D, Naccache SN, Lee D, Pfaller J, Linnen JM, **Stramer SL**. Genomic assays for identification of chikungunya virus in blood donors, Puerto Rico, 2014. *Emerg Inf Dis* 2015; 21:1409-13.
  148. Matos D, Tomashek KM, Perez-Padilla J, Muñoz-Jordán J, Hunsperger E, Horiuchi K, Noyd D, Winton C, Foster GA, Lanteri MC, Linnen JM, **Stramer SL**. Probable and possible transfusion-transmitted dengue associated with NS1-antigen negative but RNA-confirmed-positive red blood cells. *Transfusion*

2015;56:215-22.

149. Petrik J, Lozano M, Seed CR, Faddy HM, Keller PS, Prado Scuracchio PS, Wendel S, Andonov A, Fearon M, Delage G, Zhang J, Shih JWK, Gallian P, Djoudi R, Tiberghien P, Izopet J, Dreier J, Vollmer T, Knabbe C, Aggarwal R, Goel A, Ciccaglione AR, Matsubayashi K, Satake M, Tadokoro K, Jeong S-H, Zaaigre HL, Zhiburt E, Chay J, Teo D, Chua SS, Piron M, Sauleda S, Echevarria J-M, Dalton H, **Stramer SL**. Hepatitis E. *Vox Sanguinis* 2015;110:93-103.
150. **Stramer SL**, Moritz ED, Foster GA, Ong E, Linnen JM, Hogeman BM, Mak MY, Chia CP, Dodd RY. Hepatitis E virus: seroprevalence and frequency of viral RNA detection among U.S. blood donors. *Transfusion* 2015;56:481-8.
151. Greninger AL, Naccache SN, Federman S, Yu G, Mbala P, Bres V, Stryke D, Bouquet J, Somasekar S, Linnen JM, Dodd R, Mulembakani P, Schneider BS, Muyembe-Tamfum JJ, **Stramer SL**, Chiu CY. Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis. *Genome Medicine* 2015;7:99.
152. **Stramer SL**. The potential threat to blood transfusion safety of emerging infectious disease agents. *Clin Adv Hematol Oncology* 2015;13:420-2.
153. Anez G, Heisey DAK, Chancey C, Fares RCG, Espina LM, Souza KPR, Teixeira-Carvalho A, Krysztof DE, Foster GA, **Stramer SL**, Rios M. Distribution of dengue virus types 1 and 4 in blood components from infected blood donors from Puerto Rico. *PLOS Neglected Tropical Diseases* 2016;10(2):e0004445.
154. **Stramer SL**, Yu G, Herron R, Espinoza N, Foster GA, Naccache SN, Brodsky JP, Ong E, Linnen JM, Dyer N, Styer LM, Parker MM, Chiu CY. Two human immunodeficiency virus Type 2 cases in US blood donors including serologic, molecular, and genomic characterization of an epidemiologically unusual case. *Transfusion* 2016;56:1560-68.
155. Musso D, **Stramer SL**, MP Busch. Zika virus: a new challenge for blood transfusion. *The Lancet* 2016; 387:1993-4.
156. Bish EK, Moritz ED, El-Amine H, Bish DR, **Stramer SL**. Cost-effectiveness of a *Babesia microti* blood donation intervention based on real-time prospective screening in endemic areas of the United States. *Transfusion* 2016;56:775-7.
157. Hoffman KW, Sachs D, Bardina SV, Michlmayr D, Rodriguez CA, Sum J, Foster GA, Krysztof DE, **Stramer SL**, Lim JK. Differences in early cytokine production are associated with development of a greater number of symptoms following West Nile Virus Infection. *J Infect Dis* 2016;214:634-43.
158. Grinev A, Chancey C, Volkova E, Anez G, Heisey DAR, Winkleman V, Foster GA, **Stramer SL**, Rios M. Genetic variability of West Nile Virus in US blood donors from the 2012 epidemic season. *PLOS Neglected Tropical Diseases* 2016;10(5):e0004717.
159. Garica MN, Woc-Colburn L, Rossmann SN, Townsend RL, **Stramer SL**, Bravo M, Kamel H, Beddard R, Townsend M, Oldham R, Bottazzi ME, Hotez PJ, Murray KO. *Trypanosoma cruzi* screening in Texas blood donors, 2008-2012. *Epidemiol. Infect.* 2016;144:1010-3.
160. Vahidnia F, **Stramer SL**, Kessler D, Gonzalez TT, Shaz BH, Leparac G, Krysztof DE, Dodd RY, Glynn SA, Custer B. Motivations for donating and attitudes toward screening policies in US blood donors with viral infection. *Transfusion* 2016;56:2013-20.
161. Vahidnia F, **Stramer SL**, Kessler D, Shaz B, Leparac G, Krysztof DE, Glynn SA, Custer B. Recent viral infection in US blood donors and health-related quality of life (HRQL). *Qual Life Res* 2016;26(2):349-

357.

162. Dodd RY, Notari EP, Nelson D, Foster GA, Krysztof DE, Kaidarova Z, Milan-Benson L, Kessler DA, Shaz BH, Vahidnia F, Custer B, **Stramer SL**. Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States. *Transfusion* 2016; 56:2781-89.
163. Custer B, **Stramer SL**, Glynn S, Williams AE, Anderson SA. Transfusion-transmissible infections monitoring system: a tool to monitor changes in blood safety. *Transfusion* 2016;56:1499-502.
164. Shrestha A, Flower RLP, See CR, **Stramer SL**, Faddy HM. A comparative study of assay performance of commercial Hepatitis E Virus enzyme-linked immunosorbent assay kits in Australian blood donor samples. *Journal of Blood Transfusion* 2016; doi:10.1155/2016/9657675.
165. Crowder LA, Steele WR, Notari EP 4<sup>th</sup>, Hopkins CK, Lima JL, Foster GA, Townsend RL, Krysztof DE, Dodd RY, **Stramer SL**. Prevalence, incidence, and risk factors of human immunodeficiency virus infection in blood donors in the Southeastern United States. *Transfusion* 2016; doi:10.1111/trf.13891.
166. Moritz ED, Winton CS, Tonnetti L, Townsend R, Berardi VP, Hewins ME, Weeks KE, Dodd RY, **Stramer SL**. Screening for *Babesia microti* in the US blood supply. *NEJM* 2016; 375: 2236-45.
167. Betsem E, Kaidarova Z, **Stramer SL**, Shaz B, Sayers M, LeParc G, et al. Correlation of West Nile virus incidence in donated blood with West Nile neuroinvasive disease rates, United States, 2010–2012. *Emerg Infect Dis.* 2017;23:212-9.
168. Cobb B, Simon CO, **Stramer SL**, Body B, Mitchell PS, Reisch N, Stevens W, Carmona S, Katz L, Will S, Leisenfeld O. The cobas®6800/8800 System: a new era of automation in molecular diagnostics. *Expert Rev Mol Diagn.* 2017;17:167-80.
169. Groves JA, Shafi H, Nomura JH, Herron RM, Baez D, Dodd RY, **Stramer SL**. A probable case of West Nile virus transfusion transmission. *Transfusion* 2017; doi:10.1111/trf.14018.
170. Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, **Stramer SL**, Garcia-Sastre A, Krammer F, Lim JK. Enhancement of Zika virus pathogenesis by preexisting antinflavivirus immunity. *Science* 2017; doi:10.1126/science.aal4365.
171. Leiby DA, Nguyen ML, Proctor MC, Townsend RL, **Stramer SL**. Frequency of *Trypanosoma cruzi* parasitemia among infected blood donors with a potential association between parasite lineage and transfusion transmission. *Transfusion* 2017; doi:10.1111/trf.14082.
172. Moritz ED, Hewins ME, Berardi VP, Dodd RY, **Stramer SL**. Description of 15 DNA-positive and antibody-negative “window-period” blood donations identified during prospective screening for *Babesia microti*. *Transfusion* 2017; doi:10.1111/trf.14103.

### Book Chapters

1. **Stramer SL**. Indicator systems for microbiological quality and safety of water. 1. Established viable indicator systems – fecal streptococci, and 2. Proposed viable indicators – Vaccine polioviruses. **In**, Toxicology and Oncology. Volume 7, Number 5/6. Drinking Water Pilot Project Series 1987, CCMS 128, EPA 570/9-84-006 (ISSN 0731-8898).
2. Robertson BH, Brown, VK, **Stramer SL**, Hine TK, Khanna B, Anderson LJ, Fields HA, Bradley DW, Margolis HS. Variation within hepatitis A VP1 amino acid and nucleotide sequences. **In**, Viral Hepatitis and Liver Diseases, 1988. p. 48-54. Alan R. Liss, Inc.

3. Busch MP, **Stramer SL**, Kleinman SH. Evolving application of nucleic acid amplification assays for prevention of virus transmission by blood component and derivatives. **In**, Applications of Molecular Biology to Blood Transfusion Medicine, 1997. p. 123-176. AABB, **ed.** Garratty G.
4. Busch MP, Kleinman SH, **Stramer SL**. Nucleic acid amplification testing of blood donations. **In**, Molecular Biology in Blood Transfusion. Proceedings of the 24<sup>th</sup> International Symposium on Blood Transfusion, Groningen, 1999, p. 81-103, **ed.** Smit Sibinga, CT, Klein, HG.
5. **Stramer SL**. Nucleic acid testing: The US Approach. **In**, Transfusion Microbiology, 2008. p. 203-7. Cambridge University Press.
6. Dodd RY, **Stramer SL**. Transfusion-transmitted infections. **In**, Practical Transfusion Medicine (4<sup>th</sup> Ed), 2013. p 132-143. Wiley, Chichester, **ed.** Murphy MF, Pamphilon DH, Heddle NM.
7. Dodd RY, **Stramer SL**. Transfusion-transmitted infections. **In**, Practical Transfusion Medicine (5<sup>th</sup> Ed). 2017. p 153 – 167. Wiley, Chichester, **ed.** Murphy MF, Roberts DJ, Yazer MH.

### Abstracts

1. **Stramer SL**, Starzyk MJ. Improved growth of *Thermus aquaticus* on a lysate medium. Abstracts of the American Society for Microbiology Annual Meeting, New Orleans, LA, 1977.
2. **Stramer SL**, Cliver DO. Poliovirus removal from septic systems under conditions of soil saturation. Abstracts of the American Society for Microbiology Annual Meeting, Dallas, TX, 1981.
3. Cliver DO, **Stramer SL**. Seventy-Five years of agricultural engineering, food, fiber and the future. Wisconsin's experience with on-site waste disposal. Microbiological studies of on-site disposal. Presented at the American Society of Agricultural Engineers Summer Meeting, Madison, WI, 1983.
4. **Stramer SL**, Wheeler CM, Schable CA, Musial C, Gerba CP. Comparison of the growth of stool-derived strains of hepatitis A virus. Abstracts of the American Society of Microbiology Annual Meeting, St. Louis, MO, 1984.
5. **Stramer SL**, Green KM, Cliver DO. Removal of poliovirus by sand columns and operation mound-type septic tank systems. Abstracts of the American Society for Microbiology Annual Meeting, Las Vegas, NV, 1985.
6. Wheeler CM, Fields HA, Humphrey CD, **Stramer SL**, Maynard JE. Crystallization of highly purified hepatitis A virus particles. American Society for Virology Annual Meeting, Albuquerque, NM, 1985.
7. **Stramer SL**, Bloch AB, Fields HA, Gerba CP. Isolation of hepatitis A virus from groundwater implicated in a common source outbreak. Abstracts of the American Society for Microbiology Annual Meeting, Washington, DC, 1986.
8. **Stramer SL**, Robertson BH, Anderson LA, Nainan O, Margolis HS, Fields HA. Polypeptide profiles of geographically-distinct isolates of hepatitis A virus. American Society for Virology Annual Meeting, Santa Barbara, CA, 1986.
9. Robertson BH, **Stramer SL**, Hine TK, Anderson LJ, Fields HA, Bradely DW, Margolis HS. Variation within hepatitis A (HAV) VP1 amino acid and nucleotide sequence. American Society for Virology Annual Meeting, Chapel Hill, NC, 1987.
10. **Stramer SL**, Heller JS, Coombs RW, Parry RV, Ho DD, Stewart JL, Allain JP. Detection of HIV markers prior to IgG antibody sero-positivity in plasma donors. [Abstract M.B.P.140] Abstracts of the



5th International Conference on AIDS, Montreal, Quebec, 1989.

11. **Stramer, SL**, Gibes J, Zemel E, Sachs K, Mathieu MB, Heller JS. Comparison of nine HIV-1 seroconversion donors on six HIV-1 antibody assays. [Abstract M.B.P.164] Abstracts of the 5th International Conference on AIDS, Montreal, Quebec, 1989.
12. Brooks JB, Hanson M, Kwok S, **Stramer SL**, Balfour HH, MacDonald K. HIV infection in western blot indeterminate blood donors. [Abstract T.B.P.348] Abstracts of the 5th International Conference on AIDS, Montreal, Quebec, 1989.
13. **Stramer SL**, Mathieu MB, Potthoff AE, Holzkamp SA, Shenaut JL, Mitten CJ, Heller JS. A second generation viral lysate HIV-1 EIA with improved HIV-1 and HIV-2 sensitivities. Abstracts of the 5th Consensus Conference on Testing for Human Retroviruses, Kansas City, MO, 1990.
14. Fang CT, L. Porter L, **Stramer SL**, Sandler SG. Cross reactivity between HIV-1 and HIV-2 on western blot (WB). [Abstract]. ISBT and AABB Joint Congress, Los Angeles, CA, 1990.
15. **Stramer SL**, Mitten CJ, Mathieu MB, Potthoff AE, Fang CT. Improved sensitivity of Abbott HIVAB HIV-1 EIA (viral) in laboratories across the US. [Abstract]. BT and AABB Joint Congress, Los Angeles, CA, 1990.
16. Wu P, Miller B, High C, **Stramer SL**, Troonen H, Mucke K, Schoen R. A screening assay for antibodies to HIV-1 and HIV-2 using recombinant antigens. [Abstract]. ISBT and AABB Joint Congress, Los Angeles, CA, 1990.
17. **Stramer SL**, Potthoff AE, Mathieu MB, Mitten CJ, Allain JP, Fang CT, Tegtmeier GE. Cross reactivity of Abbott HIVAB HIV-1 EIA (viral) to HIV-2 antibodies. [Abstract]. ISBT and AABB Joint Congress, Los Angeles, CA, 1990.
18. **Stramer SL**, Downey C, Allain JP. Presence of HIV antibody in diluted urine using a viral-based HIV-1 EIA kit having improved sensitivity. Abstracts of the 6th International Conference of AIDS, San Francisco, CA, 1990.
19. Wu P, High C, **Stramer SL**, Troonen H, Mucke K, Schoen R. A screening assay for antibodies to HIV-1 and HIV-2 using recombinant antigens. Abstracts of the 6th International Conference of AIDS, San Francisco, CA, 1990.
20. Peterson B, Kits A, Lainio S, Wiese J, Phelps B, Plich J, **Stramer SL**. Improved HIV-1 seroconversion sensitivity in an automated assay for detection of antibodies to HIV-1 and HIV-2. Abstracts of the 8th III International Conference on AIDS, Amsterdam, The Netherlands, 1992.
21. Ginsburgh C, Hall-Steele G, Nordmark K, Pawlowski J, Ruff S, Stumpf R, Webber S, **Stramer SL**. A rapid automated immunoassay for the detection of antibodies to HIV-1 and HIV-2 utilizing recombinant antigens. Program and Abstracts of the 5th National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases, Atlanta, GA, 1992.
22. Holzer T, Staller J, Dillender M, Pandy L, Mazurkiewicz K, **Stramer SL**. False positive EIA reactivity in multiple blood bank screening assays following influenza vaccination. Program and Abstracts of the 5th National Forum on AIDS, Hepatitis and Other Blood Borne Diseases, Atlanta, GA, 1992.
23. Nichols D, Sapan C, **Stramer SL**, Liu D. Comparative evaluation of Abbott HIV-1/HIV-2 (rDNA). Abbott HIV-1 EIA and Genetic Systems HIV-1/HIV-2 EIA for detection of antibodies to HIV in seroconversion panels. Program and Abstract of the 5th National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases, Atlanta, GA, 1992.

24. Piotrowski S, Przybylski C, Wiesner D, Stewart J, **Stramer SL**. Immune complex disruption of HIV-1 antigen testing. [Abstract]. Program and Abstracts of the 5th National Forum on AIDS, Hepatitis and Other Blood-Borne Diseases, Atlanta, GA, 1992.
25. Dillender M, Dawson G, Holzer T, Chau K, **Stramer SL**. False positive EIA reactivity in multiple blood bank screening assays is due to nonspecific binding of IgM. Program and Abstracts of the 5th National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases, Atlanta, GA, 1992.
26. Weiblen B, Schumacher R, Garrett P, Holzer T, Dillender M, **Stramer SL**. False reactivity in viral marker antibody assays following influenza vaccination is due to IgM interference. Program and Abstracts of the 5th National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases, Atlanta, GA, 1992.
27. Holzer TJ, Staller JM, Dillender MJ, **Stramer SL**. False positive EIA reactivity in multiple blood screening assays following influenza vaccination: [Abstract]. *Transfusion* 1992;32(Suppl):67S.
28. **Stramer SL**, Dillender MJ, Pandy LM, Holzer TJ. False positive EIA reactivity in multiple blood bank screening assays is due to non-specific binding of IgM. [Abstract] *Transfusion* 1992;32(Suppl):30S.
29. Bentley NL, Zuck TF, **Stramer SL**. Evaluation of lipemic and non lipemic samples using the Abbott anti-HIV-1/2 enzyme immunoassay. [Abstract]. *Transfusion* 1993;33(Suppl):36S.
30. Blosser J, Tegtmeier G, Henderson S, Bayer W, **Stramer SL**. Detection of HTLV positive blood donors with licensed and unlicensed HTLV-1 ELISA test kits. [Abstract]. *Transfusion* 1993;33(Suppl):38S.
31. **Stramer SL**, Dillender MJ, Coleman CL, Tegtmeier GE, Contoreggi C, Meyer WA, Fang CT. Detection of antibodies to HTLV-I and HTLV-II in high-risk and endemic populations using an HTLV-I EIA. [Abstract]. *Transfusion* 1993;33(Suppl):39S.
32. **Stramer SL**, Dillender MJ, Coleman CL, Fang CT, Tegtmeier GE, Cyrus S, Hielle B. Comparison of HTLV-I antigen containing test kits for detection of antibodies of HTLV-I and HTLV-II. [Abstract]. *Transfusion* 1993;33(Suppl):39S.
33. **Stramer SL**, Coleman CL, Wieblen BJ, Gallo D. Specificity studies of HTLV western blots in Caribbean blood donors and U.S. intravenous drug users (IVDU). [Abstract]. *Transfusion* 1993; 33(Suppl):39S.
34. Henderson S, Tegtmeier G, Bayer W, **Stramer SL**, Sapan C. HIV immunofluorescence assay (IFA) to confirm anti-HIV-1/2 EIA reactive blood donor samples. [Abstract]. *Transfusion* 1994;34 (Suppl):35S.
35. Henrard DR, Phillips J, Phelps BH, **Stramer SL**, Swanda S, Gilcher RO. Detection of HIV p24 antigen and plasma RNA can identify true HIV-1 infection among EIA reactive/ seroindeterminate specimens. [Abstract]. *Vox Sanguinis* 1994;67(Suppl):30.
36. **Stramer SL**, Sapan CV, Henderson SE et al. Commercial HIV-immunofluorescence assay (IFA) in confirmatory algorithms for HIV-1/2 EIA. Meeting of the International Society of Blood Transfusion, Amsterdam, The Netherlands, 1994.
37. Busch MP, Herman SA, Henrard DR, Satten GA, Sakahara NS, **Stramer SL**, Garrett P, Schumacher R. Time course and kinetics of HIV viremia during primary infection. Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C, 1996.
38. Busch MP, Schumacher RT, **Stramer SL**, Garrett PE. Consistent sequential detection of RNA, antigen and antibody in early HIV infection: assessment of the window period. XI International Conference on AIDS, Vancouver, Canada, 1996.

39. **Stramer SL**, Salemi BL, Sievert WS, Lackritz EM, Schable CA, Busch MP. Evaluation of U.S. blood donations testing positive for HIV-1 p24 antigen (p24). [Abstract]. *Transfusion* 1996;36 (Suppl):38S.
40. **Stramer SL**, Garrett PE, Schumacher RT, Acker J, Weiblen BJ, Busch MP. HIV p24 antigen stability in plasma in the absence or presence of early HIV antibody. [Abstract]. *Transfusion* 1996;36 (Suppl):39S.
41. Busch MP, Satten GA, Herman SA, Sakahara NS, Garrett PE, **Stramer SL**, Schumacher R. HIV plasma RNA for confirmation of HIV-1 p24 Ag/anti-HIV reactivity in seroconverting (SC) 3 donors. [Abstract]. *Transfusion* 1996;36(Suppl):41S.
42. Busch MP, Schumacher RT, **Stramer SL**, Garrett PE, Weiblen BJ. Assessment of the window period: detection of RNA, p24 antigen and antibody in early infection. [Abstract]. *Transfusion* 1996;36 (Suppl):42S.
43. **Stramer SL**, Lackritz EM, Busch MP. Yield of detection of HIV-1 infected US blood donors by p24 antigen (Ag) screening. [Abstract]. 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C, 1997.
44. Kleinman SH, Busch MP, **Stramer SL**. First year experience with HIV p24 antigen (Ag) testing: Ag indeterminate donors are not infected with HIV. [Abstract 1816] *Blood* 1997;1(Suppl):408a.
45. **Stramer SL**, Kleinman SH, Busch MP. Rate of HIV antibody false-positive (FP) western blots (WB) and correlation with WB band pattern. [Abstract]. *Transfusion* 1997;37(Suppl):98S.
46. **Stramer SL**, Aberle-Grasse J, Brodsky JP, Busch MP, Lackritz EM. US blood donor screening with p24 antigen (Ag): one year experience. [Abstract]. *Transfusion* 1997;37(Suppl):1S.
47. **Stramer SL**, Dodd RY, Lee TH, Busch MP. HLA typing techniques and HIV envelope (env) sequence analysis resolve difficulties in sample identification during HIV-1 p24 antigen (Ag) neutralization (Neut) testing. [Abstract]. *Transfusion* 1997;37(Suppl):55S.
48. **Stramer SL**, Porter RA, Brodsky JP, Conrad A, Smith RIF, Dodd RY. Sensitivity of HIV and HCV RNA detection by pooled PCR testing. [Abstract]. *Transfusion* 1997;37(Suppl):98S.
49. Dodd RY, Griffin GD, Conrad A, Smith RIF, Page PL, **Stramer SL**. Pilot study to determine the feasibility of PCR testing of pooled donor samples for HBV, HCV, HAV and parvovirus B19. [Abstract]. *Transfusion* 1997;37(Suppl):1S.
50. Sullivan M, Williams A, Guido E, Mettler R, Schable C, **Stramer SL**. Detection and characterization of an HIV type 2 antibody positive blood donor in the U.S. [Abstract]. *Transfusion* 1997;37(Suppl):58S.
51. Aberle-Grasse J, Williams AE, Musavi F, **Stramer SL**. Decreasing annual HIV seroprevalence among allogeneic blood donations. [Abstract]. *Transfusion* 1997;37(Suppl):110S.
52. Busch M.P, **Stramer SL**, Garcia J, Lerner W, Heneine W. Use of a PCR amplified reverse transcriptase assay (Amp-RT) to rule out occult retrovirus infection in donors with positive HIV p24 antigen neutralization results. [Abstract]. *Transfusion* 1997;37(Suppl):109S.
53. Busch MP, B. Rawal D, **Stramer SL**, Satten GA, Janssen RS. Estimation of HIV incidence in blood donors using a detuned anti-HIV EIA test strategy. [Abstract]. *Transfusion* 1997;37(Suppl):109S.
54. Griffin GD, **Stramer SL**, Rutter PA, Lenoir DJ, Kresken MM, Platte RC. One year evaluation of viral marker test failures across multiple test sites. [Abstract]. *Transfusion* 1997; 37(Suppl):100S.
55. Kleinman SH, Busch MP, **Stramer SL**, Watanabe K, Use of HIV-1/HIV-2 recombinant immunoblot

assay (RIBA) to resolve infection status of donors with possible false positive (FP) HIV western blots (WB). [Abstract]. Transfusion 1997;37(Suppl):47S.

56. Tobler LH, Lee SR, **Stramer SL**, Watanabe K, Busch MP. Importance of RIBA 3 vs 2 for confirmation of HCV 3 EIA reactive blood donations. [Abstract]. Transfusion 1997;37(Suppl):48S.
57. Tobler LH, **Stramer SL**, Kleinman SH, Kockesky R, Peterson J, Watanabe K, Lee SR. Yield of HCV EIA-3.0 vs EIA-2.0 in screening US blood donations. [Abstract]. Transfusion 1997;37(Suppl):111S.
58. **Stramer SL**, Porter PA, Brodsky JP, Waldman KJ, Pollack SR, Dodd RY, Smith RIF, Billyard B, Rainin L. Stability of HCV RNA for pooled genome amplification testing (GAT). Vox Sang 1998;74 (Suppl):10.
59. **Stramer SL**, Porter RA, Brodsky JP, Waldman KJ, Dodd RY, Smith RIF, Billyard B. Sensitivity of HIV and HCV RNA Detection by Pooled Genome Amplification Testing (GAT). Vox Sang 1998;74(Suppl):1102.
60. **Stramer SL**, Salemi B, Brodsky JP, Sakarhara N, Busch MP. Comparison of four seroconverting blood donors identified by HIV-1 p24 antigen (Ag) screening. [Abstract]. Transfusion 1998; 38(Suppl):2S.
61. **Stramer SL**, Porter RA, Brodsky JP, Waldman KJ, Dodd RY. Sensitivity of HIV and HCV RNA detection by pooled genome amplification testing (GAT). [Abstract]. Transfusion 1998;38(Suppl): 70S.
62. **Stramer SL**, Porter RA, Brodsky JP, Waldman KJ, Pollack SR, Dodd RY. Stability of HCV RNA for pooled genome amplification testing (GAT). [Abstract]. Transfusion 1998;38(Suppl):71S.
63. Busch MP, Aberle-Grasse J, Rawal BD, **Stramer SL**, Williams AE, Satten GA, Janssen RS. Sensitivity of confidential unit exclusion and anti-HBc and syphilis tests for detection of recent vs. longstanding HIV infection in blood donors. [Abstract]. Transfusion 1998;38(Suppl):72S.
64. Kleinman S, Busch M, Williams A, Watanabe K, **Stramer SL**, Sayre K. Use of IFA to resolve HIV-1 infection status of HIV western blot (WB) positive (POS) samples lacking p31. [Abstract]. Transfusion 1998;38(Suppl):80S.
65. Busch MP, Aberle-Grasse J, Rawal BD, **Stramer SL**, Williams AE, Satten GA, Janssen RS. Demographic correlates of HIV of HIV incidence among first-time blood donors. [Abstract]. Transfusion 1998; 38(Suppl):81S.
66. **Stramer SL**, Aberle-Grasse J, Dodd RY. HIV, HBV and HCV incidence and prevalence rates in U.S. whole blood donors. [Abstract]. Transfusion 1998;38(Suppl):81S.
67. **Stramer SL**, Layug L, Trenbeath J, Brodsky JP, Peoples B, Delaney S, Henderson S, Vance K, Tegtmeier GE. Use of a second EIA in an HTLV-I/HTLV-II Algorithm. [Abstract]. Transfusion 1998; 38(Suppl):81S.
68. Tegtmeier GE, Edwards RL, Blosser JK, Smith RIF, Dodd RY, Page PL, **Stramer SL**. Effect on blood safety of product quarantine of prior collections from donors who seroconvert to Anti-HBc. [Abstract]. Transfusion 1998;38(Suppl):91S.
69. **Stramer SL**, Rutter P, Taylor L, Brodsky J, Winton C, Page PL. Use of a second EIA in an HBsAg confirmatory algorithm. [Abstract]. Transfusion 1998;38(Suppl):92S.
70. **Stramer SL**, Duncan O, Brodsky JP, Winton C. Results of the use of an HCV version 3.0 supplemental test. [Abstract]. Transfusion 1998;38(Suppl):94S.
71. **Stramer SL**, Porter RA, Brodsky JP, Waldman KJ, Dodd RY, Armstrong T, Griffin GD. Replacement of

HIV-1 p24 antigen screening with HIV-1 RNA nucleic acid testing (NAT) for whole blood donations. [Abstract]. *Transfusion* 1999;39(Suppl):2S.

72. Armstrong T, **Stramer SL**, Brodsky JP, Waldman KJ, Lattyak MM, Griffin GD. Analysis of gravimetric dispense volume verification of blood donor pools for nucleic acid testing (NAT). [Abstract]. *Transfusion* 1999;39(Suppl):65S.
73. **Stramer SL**, Waldman KJ, Brodsky JP, Porter RA, Davis JT, Peoples B, Dodd RY, Armstrong T, Griffin GD. Investigational screening of whole blood donations for HIV-1 and HCV by nucleic acid testing (NAT). [Abstract]. *Transfusion* 1999;39(Suppl):84S.
74. **Stramer SL**, Davis JT, Brodsky JP, Therese A, Griffin GD, Waldman KJ. Performance characteristics of the Gen-Probe HIV-1/HCV TMA Assay used for blood donor screening. [Abstract]. *Transfusion* 1999;39(Suppl):84S.
75. Griffin GD, **Stramer SL**, Armstrong T, Griswold JH, Kresken MM, Lenoir DJ, Waldman KJ, Fipps DR, Platte RC. Invalid (INV) and aborted (ABT) rates experienced with viral marker screening assays and nucleic acid testing (NAT). [Abstract]. *Transfusion* 1999;39 (Suppl):93S.
76. Busch MP, Kleinman SH, **Stramer SL**, Williams AE, Tobler LH, Todd DS, Quan S, Phelps H. False positive HTLV-I/II supplemental test results in blood donors. [Abstract]. *Transfusion* 1999;39(Suppl):105S.
77. Tobler LH, **Stramer SL**, Cyrus SJ, Porter RA, Caglioti S, Prince HE, Todd DS, Quan S, Phelps BH, Busch MP. Accuracy of alternative EIA strategies for HTLV supplemental testing. [Abstract]. *Transfusion* 1999;39(Suppl):105S.
78. **Stramer SL**, Brodsky JP, Trenbeath J, Taylor L, Peoples B, Dodd RY. Resolution testing of HTLV-I/II screening test repeatedly reactive donor samples by the use of a dual EIA algorithm. [Abstract]. *Transfusion* 1999;39(Suppl):106S.
79. **Stramer SL**, Tobler LH, Porter R, Brodsky JP, Cyrus SJ, Caglioti S, Quan S, Phelps BH, Busch MP. Comparison of HTLV-I/HTLV-II western blot and recombinant immunoblot assay for supplemental testing of repeat reactive blood donor samples. [Abstract]. *Transfusion* 1999;39(Suppl):106S.
80. **Stramer SL**, Brodsky JP, Peoples B, Porter RA, Wiack M. Results of HCV RIBA 2.0 indeterminate testing by using HCV RIBA 3.0. [Abstract]. *Transfusion* 1999;39(Suppl):107S.
81. Tobler LH, Tegtmeier GE, **Stramer SL**, Quan S, Dockter J, Giachetti C, Busch MP. Use of HCV EIA signal-to-cutoff ratio to determine which donations warrant lookback. [Abstract]. *Transfusion* 1999; 39(Suppl):107S.
82. Griffin GD, **Stramer SL**, Griswold JH, Lenoir DJ, Kresken MM, Armstrong T, Fipps DR. Computerized tracking of laboratory testing turnaround time (TAT) across multiple testing sites. [Abstract]. *Transfusion* 1999;39(Suppl):135S.
83. Waldman KJ, Griffin GD, Kropp J, Mattingly P, Potteiger T, Lattyak MM, Peoples B, Morrow L, Davis JT, Dodd RY, **Stramer SL**. System-wide implementation of nucleic acid testing under an investigational new drug application. [Abstract]. *Transfusion* 1999;39(Suppl):142S.
84. Dodd RY, Aberle-Grasse JM, **Stramer SL**. The yield of nucleic acid testing (NAT) for HIV and HCV RNA in a population of U.S. voluntary donors: relationship to contemporary measures of incidence. [Abstract]. *Transfusion* 2000;40(Suppl):1S.
85. **Stramer SL**, Peoples BG, Preston SB, Tzeng J, Davis J, Waldman KJ. Follow-up study of donors

testing nucleic acid test (NAT) reactive for HIV or HCV. [Abstract]. Transfusion 2000;40(Suppl):3S.

86. Orton SL, Peoples BG, **Stramer SL**, Dodd RY, Alter MJ. Identification of recent risk factors among blood donors confirmed to be HCV NAT reactive, anti-HCV non-reactive. [Abstract]. Transfusion 2000; 40(Suppl):3S.
87. Aberle-Grasse JM, Dodd RY, **Stramer SL**. Recent trends in seroprevalence and incidence of HIV-1/2, HCV, and HBV in U.S. allogeneic blood donors. [Abstract]. Transfusion 2000;40(Suppl):3S.
88. Kleinman SH, **Stramer SL**, Mimms L, Phelps BH, Gallarda JL, Fang C, Busch MP. Comparison of preliminary observed yield of HCV and HIV minipool (MP) nucleic acid testing (NAT) with predictions from the incidence/window period (INC/WP) model. [Abstract] Transfusion 2000;40(Suppl):4S.
89. **Stramer SL**, Brodsky JP, Peoples BG, Preston SB, Tzeng J, Waldman KJ. Relationship of nucleic acid testing (NAT) results to HIV and HCV serology among donors; relevance to counseling. [Abstract]. Transfusion 2000;40(Suppl):31S.
90. Tobler LH, **Stramer SL**, Kleinman SH, Brodsky J, Todd D, Wu Y, Busch MP. Misclassification of HCV viremic blood donors as indeterminate by RIBA 3.0 due to human superoxide dismutase (HSOD) reactivity. [Abstract]. Transfusion 2000;40(Suppl):78S.
91. Waldman KJ, Perks C, Brodsky JP, **Stramer SL**. Impact of the inclusion of seroreactive in a nucleic acid testing (NAT) program. [Abstract]. Transfusion 2000;40(Suppl):92S.
92. Waldman KJ, Arnold MM, Steele J, Lieber MP, Anderson CM, **Stramer SL**. Successful control of product release during a phase I nucleic acid testing (NAT) program. [Abstract]. Transfusion 2000; 40(Suppl):92S.
93. **Stramer SL**, Orton SL, Brodsky JP, Dodd RY. Relationship between HCV antibody prevalence, incidence and NAT yield in donations from US blood donors. [abstract]. Transfusion 2001; 41(Suppl):2S.
94. Busch MP, Glynn SA, Wu Y, McEntire R, **Stramer SL**, Operskalski EA, Murphy EL, Kleinman SH. Demographic correlates of HCV viremia among HCV seropositive donors. [Abstract]. Transfusion 2001;41(Suppl):3S.
95. **Stramer SL**, Brodsky JP, Preston SB, Kuhns MC, Pierce MP, Smith RI. Comparative sensitivity of HBsAg and HBV NAT. [Abstract]. Transfusion 2001;41(Suppl):8S.
96. **Stramer SL**, Dodd RY, Smith RI. Parvovirus B19 and HAV screening of whole blood donations. [Abstract]. Transfusion 2001;41(Suppl):28S.
97. **Stramer SL**, Brodsky JP. Replacement of HIV-1 p24 antigen with HIV NAT; studies on HIV antibody-positive donors. [Abstract]. Transfusion 2001;41(Suppl):29S.
98. Guido EA, Lugo JF, Meny GM, **Stramer SL**. Detection of an HIV-1 confirmed-positive blood donor by NAT: A regional case study. [Abstract]. Transfusion 2001;41(Suppl):79S.
99. Vargo JM, Wang S, Fang C, Smith KM, Mimms L, Caglioti S, Gilbert D, **Stramer SL**. The Chiron Procleix HIV-1/HCV assay results are highly reproducible. [Abstract]. Transfusion 2001; 41(Suppl):84S.
100. Fang C, Vargo JM, Smith KM, Mimms L, **Stramer SL**, Caglioti S, Gilbert D, Richards W, Gammon R. Specificity analysis of a nucleic acid testing (NAT) assay on voluntary blood donors. [Abstract]. Transfusion 2001;41(Suppl):85S.

101. Busch MP, **Stramer SL**, Dodd RY, Notari EP IV, Glynn S, Wright DJ, Kleinman S. New strategy for estimating residual risk and yield of NAT screening assays. [Abstract]. *Transfusion* 2002; 42(Suppl):2S.
102. Busch MP, **Stramer SL**, Caglioti S, Tobler LH, McAuley J, Glynn S, Dodd RY. Error surveillance in blood donor infectious disease screening. [Abstract]. *Transfusion* 2002;42(Suppl):3S.
103. **Stramer SL**, Brodsky JP, Notari E, Kane K, Dodd RY. Do NAT-reactive pools that do not resolve to a NAT-reactive donation contain HIV-1 or HCV? [Abstract]. *Transfusion* 2002;42(Suppl):4S.
104. Tobler LH, **Stramer SL**, Kane K, Chein D, Arcangel P, Phelps BH, Busch MP. Reactivities of novel antigens in detecting antibody in HCV seronegative, RNA confirmed positive donors. [Abstract]. *Transfusion* 2002;42(Suppl):7S.
105. **Stramer SL**, Brodsky JP, Notari E, Dodd RY. Qualification of volunteer source plasmapheresis donations for HIV-1/HCV NAT. [Abstract]. *Transfusion* 2002;42(Suppl):8S.
106. Burch JW, Beyers ML, Liddy R, Orris ES, **Stramer SL**. Nucleic acid testing: good for recipients, good for donors. [Abstract]. *Transfusion* 2002;42(Suppl):81S.
107. Sharma U, **Stramer SL**, Wright DJ, Glynn S, Hermansen S, Schreiber G, Kleinman S, Busch MP. Impact of changes in viral marker screening assays. [Abstract]. *Transfusion* 2002;42(Suppl):85S.
108. Wissel ME, Gifford L, Preston SB, **Stramer SL**. Detection of acute hepatitis B in a plateletpheresis donor. [Abstract]. *Transfusion* 2002;42(Suppl):86S.
109. Davis JT, Brodsky JP, Armstrong T, **Stramer SL**. Results of an external quality assessment program for five laboratories performing nucleic acid testing. [Abstract]. *Transfusion* 2002;42(Suppl):88S.
110. Davis JT, Brodsky JP, Barr M, **Stramer SL**. Establishing quantitative external control ranges for a qualitative NAT assay. [Abstract]. *Transfusion* 2002;42(Suppl):88S.
111. Hasselkus-Light C, Cline J, Deza C, Luna E, Marchese A, Miller S, Getman D, **Stramer SL**, McDonough S, Mimms L, Stringfellow L. Prevalence of parvovirus B19 and hepatitis A (HAV) in pooled and individual donations. [Abstract]. *Transfusion* 2002;42(Suppl):89S.
112. Kelley VA, Phillips VL, Hillyer CD, **Stramer SL**. Increase in cost inefficiency of autologous vs. allogeneic blood given decrease in residual risk of infectious diseases: a new model. [Abstract]. *Transfusion* 2002;42(Suppl):117S.
113. **Stramer SL**, Wagner AG, Paolillo JE, Lanciotti RS, Petersen LR, Marfin AA, Dawson GJ, Guitierrez RA, Fang C, Smith RIF, Linnen JM, Giachetti C. West Nile virus (WNV) tests identify units implicated in transfusion transmission. [Abstract]. *Transfusion* 2003;43(Suppl):2A.
114. Tang Y, Hapip CA, **Stramer SL**, Fang CT. Detection and quantification of WNV RNA with a TaqMan RT-PCR assay. [Abstract]. *Transfusion* 2003;43(Suppl):3A.
115. **Stramer SL**, Beyers ML, Wagner AG, Dille BJ, Dawson GJ, Schochetman G, Linnen JM, Petersen LR, Marfin AA, Lambert AJ, Chambers T, Burkhalter K, Aspen SE, Lanciotti RS. West Nile virus (WNV) RNA prevalence in blood donations during the 2002 US epidemic. [Abstract S10]. *Transfusion* 2003;43(Suppl. 9S):3A.
116. **Stramer SL**, Wagner AG, Beyers ML, Vargo JM, Linnen JM, Rasmusson P, Brodsky JP, Davis JT, Armstrong TA. A West Nile virus (WNV) phase I preclinical study using frozen repository samples.

[Abstract S11]. Transfusion 2003;43(Suppl. 9S):3A.

117. Cyrus S, G. Robertson G, Caglioti S, Allmond SE, Brodsky JP, **Stramer SL**. Evaluation of an alternate HIV confirmatory testing algorithm. [Abstract S131]. Transfusion 2003;43(Suppl. 9S):39A.
118. **Stramer SL**, Chambers L, Page PL, Wagner AG, Gibble J. Third reported US case of breakthrough HIV transmission from NAT screened blood. [Abstract S134]. Transfusion 2003;43(Suppl. 9S):40A.
119. Garcia R, Dockter J, Schneider W, Kill M, Haight S, **Stramer SL**, Giachetti C. Performance of the Procleix HIV-1/HCV assay in organ and tissue donor serum specimens. [Abstract SP265]. Transfusion 2003;43(Suppl. 9S):120A.
120. **Stramer SL**, Brodsky JP, Foster GA, Paolillo JE, Wagner AG, Bremer R, Roggeman RA, James L, Reddy RL, Krysztof DE, Ratcliffe CM, Davis JT. Yield in WNV positive donors from minipool and individual donation NAT in 2003. [Abstract P5]. Transfusion 2004;44(Suppl. 9S):2A.
121. **Stramer SL**, Foster GA, Paolillo JE, Wagner AG, Dodd RY, Brodsky JP. Dynamics of WNV infection and resolution among blood donors. [Abstract S14]. Transfusion 2004;44(Suppl. 9S):6A.
122. Orton S, **Stramer SL**, Paolillo J, Dodd RY. West Nile virus interview study in US blood donors. [Abstract S17]. Transfusion 2004;44 (Suppl. 9S):7A.
123. Grinev A, Daniel S, Machuca A, **Stramer SL**, Hewlett IK, Rios M. Genetic variability in West Nile virus (WNV) isolates from the 2002 epidemic in the US. [Abstract S43]. Transfusion 2004;44(Suppl. 9S):15A.
124. Tang Y, Hapip CA, Liu B, **Stramer SL**, Fang CT. Determination of WNV nucleic acid sequences in envelope region from plasma samples of positive blood donors. [Abstract S44]. Transfusion 2004;44 (Suppl. 9S):15A.
125. **Stramer SL**, Wagner AG, Fisher AC, Estabrooks RL, Schroeder-Jenkins M, Dodd RY, Brodsky JP. Experience with an "improved" version of an HBsAg assay and reentry of associated deferred donors. [Abstract S90]. Transfusion 2004;44(Suppl. 9S):30A.
126. Fang CT, Notari EP, **Stramer SL**, Dodd RY. Yield analysis on current Anti-HBc donor deferral policy. [Abstract S92]. Transfusion 2004;44(Suppl. 9S):30A.
127. Notari EP, Dodd RY, Zou S, Brodsky JP, Paolillo JE, **Stramer SL**. Temporal patterns in HIV and HCV infection among donors by NAT and ELISA, 1999-2003. [Abstract S95]. Transfusion 2004;44(Suppl. 9S):31A.
128. Caglioti S, Robertson G, Winkelman V, Brodsky JP, McAuley J, Houghton D, **Stramer SL**, Busch MP. NAT cross-supplemental role assessment of the COBAS ampliscreen and Procleix TMA HIV-1 and HCV assays using initial reactive donor specimens. [Abstract SP188]. Transfusion 2004;44(Suppl. 9S):87-8A.
129. Linnen JM, Wu W, Shih MS, Broulik A, Miller S, Lewis M, Cass M, Cline J, Alden M, Magic S, Powell L, Roper P, Ford K, Riggins K, Perry E, Rhamy J, Gasuad K, Stringfellow L, Dickson S, Atlas D, Miller D, **Stramer SL**, Giachetti C. Improved specificity of the Procleix WNV assay using a modified probe reagent formulation. [Abstract SP374]. Transfusion 2004;44(Suppl. 9S):139A.
130. Rios M., Daniel S, **Stramer SL**, Caglioti S, Wood O, Hewlett IK. West Nile virus NAT-positive human plasma containing WNV-IgM and IgG antibodies can infect Vero cells and human primary macrophages in culture. [Abstract S2]. Transfusion 2005;45 (Suppl. 3S):3A.



131. Rios M, **Stramer SL**, Daniel S, Hewlett IK. West Nile virus adheres to human red blood cells (RBCs) in whole blood. [Abstract S3]. *Transfusion* 2005;45 (Suppl. 3S):3A.
132. Grinev A, Daniel S, **Stramer SL**, Caglioti S, Hewlett IK, Rios M. Genetic variability in West Nile virus (WNV) isolates from blood donors specimens from 2002, 2003 and 2004 USA Epidemics. [Abstract S6]. *Transfusion* 2005;45 (Suppl. 3S):4A.
133. Stearns FM, **Stramer SL**, Alvarez AW. Verification of visual lipemia sample suitability by quantitative triglyceride testing. [Abstract SP199]. *Transfusion* 2005;45 (Suppl. 3S):89A.
134. **Stramer SL**, Pierce MP, Strong DM, Nelson KA, Davis JT. Screening of tissue donors for detection of HIV-1, HCV and WNV RNA and HBV DNA. [Abstract SP224]. *Transfusion* 2005;45 (Suppl. 3S):96A.
135. McAuley JD, Caglioti S, Robertson G, Glanzer T, Williams R, Sarkissian V, Bayer B, Reynolds W, Powell L, Dockter J, Estes P, Wang S, Baker C, McCormick MK, Giachetti C, Armstrong G, **Stramer SL**. Multi-site study of the Procleix<sup>®</sup> Ultrio<sup>™</sup> Assay using the enhanced semi-automated system compared with the TIGRIS<sup>®</sup> automated system. [Abstract SP227]. *Transfusion* 2005;45 (Suppl. 3S):97A.
136. McAuley JD, Caglioti S, Robertson G, Glanzer T, Williams R, Sarkissian V, Bayer B, Dickey WC, Powell L, Rossi A, Estes P, Baker C, Cline J, McCormick MK, Linnen JM, Giachetti C, Armstrong G, **Stramer SL**. Multi-site study of the Procleix<sup>®</sup> WNV Assay using the enhanced semi-automated system compared with the TIGRIS<sup>®</sup> automated system. [Abstract SP420]. *Transfusion* 2005;45 (Suppl. 3S):150A.
137. Tang Y, Liu B, Taylor AL, Hapip CA, Fang CT, **Stramer SL**. Comparisons of genomic sequences of West Nile virus isolated from infected blood donors. [Abstract SP422]. *Transfusion* 2005;45 (Suppl. 3S):151A.
138. Rios M, Daniel S, **Stramer SL**, Caglioti S, Wood O, Hewlett IK. Protective role of nature antibodies in WNV infection: *in vitro* infectivity of WNV ID NAT reactive plasmas containing specific antibodies (IgM and/or IgG). [Abstract P097]. *Vox Sanguinis* 2006;91(Suppl. 3):72.
139. **Stramer SL**, Foster GA, Brodsky JP, Caglioti SG, Strong DM. Yield of minipool and individual donation nucleic acid amplification testing for West Nile virus RNA in United States blood donors, 2003-2005. [Abstract P098]. *Vox Sanguinis* 2006;91 (Suppl. 3):72.
140. **Stramer SL**, Brodsky JP, Caglioti S, Strong DM. Confirmation of infection among donors identified by minipool and individual donation nucleic acid testing (NAT) for West Nile virus (WNV) in the United States from 2003-2005. [Abstract P5]. *Transfusion* 2006;46 (Suppl. 9S):2A.
141. **Stramer SL**, Brodsky JP, Notari EP, Caglioti S, Strong DM, Confer DL, Carr-Greer A. Validation of minipool (MP) NAT as opposed to individual donation (ID) of hematopoietic stem/progenitor cells (HPCs). [Abstract S14]. *Transfusion* 2006;46 (Suppl. 9S):7A.
142. Brennan CA, **Stramer SL**, Holzmayer V, Yamaguchi J, Foster GA, Notari EP, Zou S, Dodd RY, Schochetman G, Devare SG. Identification of HIV-1 non-B subtypes and antiretroviral drug resistant strains in blood donors in the United States. [Abstract S15]. *Transfusion* 2006;46 (Suppl. 9S):8A.
143. Bernardin F, **Stramer SL**, Reherrmann B, Tobler LH, Busch MP, Delwart EL. High levels of truncated HCV genomes in NAT-yield blood donors with sero-silent infections. [Abstract S40]. *Transfusion* 2006; 46 (Suppl. 9S):16A.
144. **Stramer SL**, Foster GA, Wright DJ, Luis S, Brodsky JP, Busch MP. Genotype distribution among HCV NAT yield donors and effect of genotype on RNA-antibody seroconversion window periods. [Abstract

- S41]. *Transfusion* 2006;46 (Suppl. 9S):16A.
145. **Stramer SL**, Foster GA, Vallari DS. Qualification of reentry algorithms for antibody to hepatitis B core (anti-HBc) repeat reactive (RR) donors. [Abstract S54]. *Transfusion* 2006;46 (Suppl. 9S):21A.
  146. **Stramer SL**, Foster GA, Notari EP. HBV DNA PCR positive rates of antibody to hepatitis B core (anti-HBc) repeat reactive (RR) donors; implications for reentry protocols. [Abstract S55]. *Transfusion* 2006; 46 (Suppl. 9S):21A.
  147. Rios M, Daniel S, Wood O, Hewlett IK, Caglioti S, **Stramer SL**. Update on investigations of the infectivity of West Nile Virus (WNV) in the presence of human specific antibodies to WNV. [Abstract S70]. *Transfusion* 2006;46 (Suppl. 9S):26A.
  148. Rios M, Grinev A, Daniel S, **Stramer SL**, Hewlett IK, Rossmann SN, Caglioti S. Genetic variability of West Nile virus (WNV) in human infection. [Abstract S71]. *Transfusion* 2006;46 (Suppl. 9S):26A.
  149. **Stramer SL**, Foster GA, Brodsky JP, Dodd RY. Testing recovered plasma donations for B19 Erythrovirus (Parvovirus) DNA and hepatitis A Virus (HAV) RNA; implications for blood safety. [Abstract S101]. *Transfusion* 2006;46 (Suppl. 9S):37A.
  150. Linden JV, Burns AE, Burch JW, Schiff J, Van Vliet DL, Tegtmeier GE, **Stramer SL**. A case of acute hepatitis B associated with blood from a donor subsequently deferred for anti-HBc. [Abstract SP187]. *Transfusion* 2006;46 (Suppl. 9S):97A.
  151. Robertson G, Williams JD, **Stramer SL**, Harris W, Reynolds B, Atkinson ME, Smith JW, Linnen J, Magic S, Powell L. Multi-site clinical evaluation of Procleix<sup>®</sup> WNV assay on the semi-automated system. [Abstract SP395]. *Transfusion* 2006;46 (Suppl. 9S):163A.
  152. **Stramer SL**, Foster GA, Herron RM, Lieby DA, Crull K, Kahm P, Rader F, Morgan LJ, Caglioti S. US blood donor screening for *Trypanosoma cruzi*: clinical studies and early assessment of prevalence. [Abstract P2]. *Transfusion* 2007;47 (Suppl. 9S):1A.
  153. Grinev A, Daniel S, **Stramer SL**, Rios M. Genetic study of West Nile Virus (WNV) human isolates from 2006 reveals a new isolate carrying a deletion at the 3' NCR. [Abstract S59]. *Transfusion* 2007;47 (Suppl. 9S):24A.
  154. Mohammed H, **Stramer SL**, Tomashek K, Muñoz J, Linnen JM, Petersen L. Prevalence of dengue virus nucleic acid in blood donors in Puerto Rico. [Abstract S60]. *Transfusion* 2007;47 (Suppl. 9S):25A.
  155. Martin LA, **Stramer SL**, Kuhns MC, Schochetman G, Devare SG. Improved PRISM<sup>®</sup> HBV surface antigen assay: enhanced sensitivity leads to incremental detection of HBsAg-positive blood donors. [Abstract S74]. *Transfusion* 2007;47 (Suppl. 9S):30A.
  156. Tegtmeier GE, Katz LM, **Stramer SL**, Strong DM. Feasibility of reentry of donors deferred for repeated detection of antibody to hepatitis B core antigen (anti-HBc). [Abstract S75]. *Transfusion* 2007;47 (Suppl. 9S):30A.
  157. Zou S, **Stramer SL**, Notari EP, Musavi F, Fang T, Dodd RY. Estimating current incidence of hepatitis B viral infection among blood donors through a novel approach. [Abstract 2C-S10-03]. *Vox Sanguinis* 2008;95 (Suppl. 1):22.
  158. **Stramer SL**, Townsend RL, Foster GA, Krysztof DE, Noedel J, Caglioti S, Nguyen M, Procter MC, Leiby DA. US blood donor screening for *Trypanosoma cruzi*: clinical studies and first year experience. [Abstract P651]. *Vox Sanguinis* 2008;95 (Suppl.1):296.

159. **Stramer SL**, Foster GA, Townsend RL, Krysztof DE, Notari EP, Trouern-Trend J, Brodsky J, Lenes B, Nguyen M, Proctor MC, Bet A, Leiby DA, Rouault C, Dodd RY. *Trypanosoma cruzi* antibody screening in US blood donors: one year experience at the American Red Cross. [Abstract P5-020A]. Transfusion 2008;48(Suppl. 2S):2A.
160. Bet A, Notari EP, Townsend RL, **Stramer SL**, Leiby DA. *Trypanosoma cruzi* blood screening: Preliminary observations on infection rates associated with directed donations and congenital infection. [Abstract S39-020E]. Transfusion 2008;48 (Suppl. 2S):16A.
161. Proctor MC, Nguyen M, **Stramer SL**, Leiby DA. Detection of *Trypanosoma cruzi* parasites in US blood donors by PCR and hemoculture. [Abstract S41-020E]. Transfusion 2008;48 (Suppl. 2S):16A.
162. **Stramer SL**, Foster GA, Krysztof DE, Dodd RY. Evaluation of triggering strategies for single unit NAT West Nile virus. [Abstract S60-030D]. Transfusion 2008;48 (Suppl. 2S):23A.
163. Grinev A, Daniel S, Akolkar N, Chancey C, **Stramer SL**, Ball C, Land KJ, Rios M. New West Nile virus subtype found in Idaho isolates from humans, mosquitoes and birds in 2006 and 2007. [Abstract S63-030D]. Transfusion 2008;48 (Suppl. 2S):24A.
164. Zou S, Notari EP, Fang C, **Stramer SL**, Dodd RY. Current value of serologic test for syphilis as a surrogate marker for bloodborne viral infections among US blood donors. [Abstract S89-030K]. Transfusion 2008;48 (Suppl. 2S):34A.
165. **Stramer SL**, Foster GA, Brodsky J, Alyateem K, Barr M, Dickson S, Harris W, Hrovat T, Krysztof DE, Parmeley M, Townsend RL, Linnen J, Blunt J. Evaluation of the yield of HBV DNA-Positive, seronegative donors using an automated HIV-1/HCV/HBV Triplex NAT Assay. [Abstract S121-040A]. Transfusion 2008;48 (Suppl. 2S):45A.
166. **Stramer SL**, Foster GA, Krysztof DE, Dodd RY, Eder AF, Notari EP, Brodsky J. Efficacy of donor reentry for HIV, HBV and HCV. [Abstract S122-040A]. Transfusion 2008;48 (Suppl. 2S):46A.
167. Delwart E, Slikas B, **Stramer SL**, Kamel H, Kessler D, Krysztof DE, Carrick D, Todd D, Kakaiya R, Busch MP. Surveillance for divergent genotypes, drug-resistance and neutralization profiles in HCV, HBV and HIV infected donors. [Abstract S138-040C]. Transfusion 2008;48 (Suppl. 2S):52A.
168. Busch MP, Vermeulen M, **Stramer SL**, Sykes W, Kamel H, Foster GA, Notari EP, Reddy R, Crookes R. Rates and characteristics of HIV "elite controller" ( HIV Ab-pos/HIV RNA-neg) donors: US and South Africa. [Abstract S140-040C]. Transfusion 2008;48 (Suppl. 2S):52A.
169. **Stramer SL**, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49:1S-29S.
170. **Stramer SL**, Townsend RL, Foster GA, Brodsky JP, Linnen JM, Coleman PF, Gerlich WH, Allain J. HBV NAT yield and donor characteristics in US blood donors; impact of vaccine breakthrough infection (VBI) and correlation with modeled yield. [Abstract P3-020A]. Transfusion 2009;49 (Suppl. 3S):1A.
171. Dorsey K, Zou S, **Stramer SL**, Notari EP, Musavi F, Dodd RY. Prevalence and incidence of HIV and HCV infections among allogeneic donations since the introduction of nucleic acid testing in the United States. [Abstract S1-010A]. Transfusion 2009;49 (Suppl. 3S):3A.
172. **Stramer SL**, Eder AF, Foster GA, Dy BA, Krysztof DE, Trouen-Trend J, Dorsey K, Zou S, Benjamin RJ, Dodd RY. Investigation of reported cases of suspected transfusion transmission of HIV. [Abstract S2-10A]. Transfusion 2009;49 (Suppl. 3S):4A.
173. Notari EP, Zou S, **Stramer SL**, Dodd RY. Incidence estimation based on seroconversion among

repeat donors: a comparison to two methods. [Abstract S104-040C]. *Transfusion* 2009;9 (Suppl. 3S):43A.

174. **Stramer SL**, Townsend RL, Foster GA, Krysztof DE, Leiby DA, Brodsky JP, Rouault C, Lenes BA, Dodd RY. Sensitivity of selective testing for antibody to *Trypanosoma cruzi*. [Abstract S38-020D]. *Transfusion* 2009;49 (Suppl. 3S):18A.
175. Leiby DA, Nguyen M, Proctor MC, Townsend RL, **Stramer SL**. Transfusion-transmitted *Trypanosoma cruzi* in the U.S.: a South American connection? [Abstract S40-020D]. *Transfusion* 2009;49 (Suppl. 3S):19A.
176. **Stramer SL**, Linnen JM, Carrick JM, Krysztof DE, McMilin KD, De Vera A, Hunsperger EA, Muñoz JL, Dodd RY. Dengue viremia in donations from Puerto Rico during the 2007 dengue outbreak. [Abstract S66-030G]. *Transfusion* 2009;49 (Suppl. 3S):28A.
177. Carrick JM, Knight J, Lontoc-Bugay C, Motta C, Wellbaum JB, Fleischer C, Muñoz JL, **Stramer SL**, Linnen JM. Highly sensitive and equivalent detection of dengue virus serotypes 1, 2, 3, and 4 with an enhanced transcription-mediated amplification assay. [Abstract S67-030G]. *Transfusion* 2009;49 (Suppl. 3S):29A.
178. **Stramer SL**, Foster GA, Townsend RL, Krysztof DE, Dodd RY. Evaluation of the yield of triggering and detragging criteria for West Nile virus (WNV) NAT. [Abstract S69-030G]. *Transfusion* 2009;49(Suppl. 3S):30A.
179. **Stramer SL**, Zou S, Foster GA, Townsend RL, Dodd RY. Symptomatology of West Nile virus (WNV) infection identified in blood donors who test reactive for WNV RNA. [Abstract S70-030G]. *Transfusion* 2009;49(Suppl. 3S):30A.
180. Citrino K, Jordan CA, Rodriguez R, Stearns FM, Davis PC, Brodsky JP, **Stramer SL**. Sensitivity and specificity evaluation of the Bio-Rad GS HIV 1/HIV-2 *PLUS O* EIA, an enzyme immunoassay for detection of human antibody to HIV-1 (groups M and O) and HIV-2, on the Ortho Summit™ System (OSS). [Abstract SP431]. *Transfusion* 2009;49 (Suppl. 3S):213A.
181. Brodsky JP, **Stramer SL**. Inversion of Abbott PRISM reagents before loading does not affect assay sensitivity. [Abstract SP442]. *Transfusion* 2009;49(Suppl. 3S):217A.
182. Zou S, Musavi F, Notari EP, **Stramer SL**, Foster GA, Krysztof DE, Dodd RY. Prevalence of major bloodborne infections among apheresis collections in the United States, 2004-2007. [Abstract SP452]. *Transfusion* 2009;49(Suppl. 3S):221A.
183. **Stramer SL**, Linnen JM, Carrick JM, Bentsen CH, Krysztof DE, Hunsperger E, Muñoz JL, Dodd RY. Dengue donor viremia determined by RNA and NS1 antigen and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. [Abstract 3E-S18-02]. *Vox Sanguinis* 2010;99 (Suppl.1):32.
184. Rios M, Grinev A, Chancey C, Sylvester D, Caglioti S, Winkelman V, Land KJ, **Stramer SL**. Genetic evolution of West Nile virus (WNV) circulating in the US from 2002-2009 allowed intensified viral spread. [Abstract 3E-S18-03]. *Vox Sanguinis* 2010;99 (Suppl.1):32-3.
185. Leiby DA, Nguyen ML, Proctor MC, Townsend RL, **Stramer SL**. Impact of *Trypanosoma cruzi* phylogenetic lineage on transfusion transmission in the United States. [Abstract 5A-S35-05]. *Vox Sanguinis* 2010;99 (Suppl.1):64.
186. Brennan A, Yamaguchi J, Devare S, Foster GA, **Stramer SL**. Expanded evaluation of blood donors in the United States for HIV-1 non-B subtypes and antiretroviral drug resistant strains: 2005-2007.

[Abstract 5D-S45-04]. Vox Sanguinis 2010;99 (Suppl.1):78.

187. Zou S, Musavi F, Notari EP, **Stramer SL**, Dodd RY. Incidence and residual risk of HIV, HCV, and HBV among U.S. apheresis donors in 2007-2008 and comparison with whole blood donors. [Abstract P-0234]. Vox Sanguinis 2010;99 (Suppl.1):177.
188. **Stramer SL**, Townsend RL, Foster GA, Krysztof DE, Leiby DA, Brodsky JP, Rouault C, Lenes BA, Dodd RY. Experience with selective testing for antibody to *Trypanosoma cruzi* following validation using universal testing. [Abstract P-601]. Vox Sanguinis 2010;99 (Suppl. 1):313-4.
189. Zou S, **Stramer SL**, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: all tests are of value but no one alone is sufficient. [Abstract P1-020A]. Transfusion 2010;50 (Suppl. 2S):1A.
190. Tobler LH, Vermeulen M, **Stramer SL**, Wu S, Busch MP. Distribution of HIV viral loads in US (Clade B) and South Africa (Clade C) NAT yield donors. [Abstract S1-010A]. Transfusion 2010;50 (Suppl. 2S):3A.
191. Stearns FM, Ashwin L, Brodsky JP, Krysztof DE, **Stramer SL**. Elevated repeat reactive rates with the Abbott HIV O Plus blood donor screening assay. [Abstract S3-010A]. Transfusion 2010;50 (Suppl. 2S):4A.
192. Keating SM, Heitman JW, Norris PJ, **Stramer SL**, Kuhns MC, Mullen C, Chiklis GR, Busch MP. Cytokine and chemokine responses in the acute phase of HBV replication in vaccine breakthrough infections in blood donors. [Abstract S36-020D]. Transfusion 2010;50 (Suppl. 2S):18A.
193. Grinev A, Lu Z, Chancey C, Daniel S, Caglioti S, Winkelman V, Land KJ, **Stramer SL**, Rios M. Genetic variability of West Nile virus in the U.S., 2002-2009. [Abstract S37-020D]. Transfusion 2010;50 (Suppl. 2S):19A.
194. **Stramer SL**, Miller D, Dickson S, Colon GM, Merced C, Hunsperger EA, Muñoz JL, Lanteri MC, Tobler LH, Bentsen C. Investigational dengue virus blood donor screening in Puerto Rico with an NSI antigen test. [Abstract S39-020D]. Transfusion 2010;50 (Suppl. 2S):19A-20A.
195. Wang X, Zhao J, Ye Z, **Stramer SL**, Krysztof DE, Winton C, Hewlett IK. Absences of detectable H1N1 viremia in blood donor samples collected during the 2009-2010 pandemic period. [Abstract S40-020D]. Transfusion 2010;50 (Suppl. 2S):20A.
196. Zou S, Notari EP, **Stramer SL**, Rios J, Musavi F, Dodd RY. Trends in autologous donations. [Abstract S41-020D]. Transfusion 2010;50 (Suppl. 2S):20A.
197. Cantey PT, **Stramer SL**, Kamel H, Currier M, Townsend RL, Winton C, Ofafa KN, Steurer FJ, Todd C, Montgomery S. The U.S. *Trypanosoma cruzi* infection study: evidence for autochthonous *Trypanosoma cruzi* transmission among United States blood donors. [Abstract S70-030F]. Transfusion 2010;50 (Suppl. 2S):32A.
198. Erwin JL, Krueger NX, Ndao M, Leiby DA, **Stramer SL**, Levin AE. Sensitive and specific immunoblot assay for detection of *T. cruzi* antibodies in serum samples. [Abstract SP379]. Transfusion 2010;50 (Suppl. 2S):198A.
199. **Stramer SL**, Notari EP, Townsend RL, Custer B, Kamel H, Busch MP, Dodd RY. No evidence of *Trypanosoma cruzi* incidence in US blood donors: A 4-year study. [Abstract P1-020A]. Transfusion 2011;51(Suppl. 3S):1A.
200. **Stramer SL**, Foster GA, Boucher CB, Miller D, Dickson SS, Lenes BA, Carrick JM, Linnen J, Lanteri

MC, Bentsen C. Comparing the yield of dengue viremic blood donations using NS1 Antigen (Ag) and NAT. [Abstract S2-010A]. *Transfusion* 2011;51(Suppl. 3S):4A.

201. Dodd RY, **Stramer SL**, Dorsey K, Moritz E, Zou S, Wu Y, Qiu X, Swanson PA, Schochetman G, Hackett JR. No serologic evidence of transmission of XMRV by transfusion using a linked donor-recipient repository. [Abstract S6-010A]. *Transfusion* 2011;51(Suppl. 3S):6A.
202. Dorsey K, Moritz E, Zou S, Eder AF, **Stramer SL**. A comparison of HIV and HCV marker rates for directed vs. volunteer blood donations to the American Red Cross during 2005-2010. [Abstract S32-020D]. *Transfusion* 2011;51(Suppl. 3S):16A.
203. Sabino EC, Lee T, Leiby DA, Montalvo L, Nguyen M, **Stramer SL**, Vinelli E, Mathias L, Carrick DM, Busch MP. *T. cruzi* antibody reactivity by screening EIA correlates with rates of PCR positivity among seroreactive blood donors in the US, Brazil and Honduras. [Abstract S62-030F]. *Transfusion* 2011;51 (Suppl. 3S):28A.
204. Kaesdorf BA, **Stramer SL**, Gordon S, Kalmin ND, Williams D, Sullivan S, Kosevich M, Du S, Yen J. Clinical evaluation of the *Trypanosoma cruzi* antigen assay. [Abstract SP406]. *Transfusion* 2011;51 (Suppl. 3S):196A.
205. Añez G, Chancey C, Espina LM, **Stramer SL**, Rios M. Dengue virus bound to red blood cells of viremic blood donors retains its infectivity in cell culture. [Abstract SP429]. *Transfusion* 2011;51 (Suppl. 3S):205A.
206. Delwart E, Slikas B, **Stramer SL**, Kamel H, Kessler D, Krysztof DE, Tobler LH, Carrick DM, Wright DJ, Busch MP. Genetic diversity of recently acquired and prevalent HIV, HBV, and HCV infections in U.S. blood donors. [Abstract SP434]. *Transfusion* 2011;51(Suppl. 3S):207A.
207. Dorsey KA, Page PL, Steele WR, Krysztof DE, Foster GA, Dy BA, Eder AF, Dodd RY, **Stramer SL**. Investigation of cases of suspected transfusion transmission of human immunodeficiency virus reported to the American Red Cross. [Abstract P-331]. *Vox Sanguinis* 2012;103(Suppl.1):172-3.
208. Steele WR, Townsend RL, Lenes BA, Krysztof DE, Brodsky JP, Dodd RY, **Stramer SL**. *Trypanosoma cruzi* antibody screening in U.S. blood donors: four-year experience and characterization of antibody reactive donors. [Abstract P-354]. *Vox Sanguinis* 2012;103(Suppl.1):180.
209. Benjamin RJ, **Stramer SL**, Leiby DA, Dodd RY, Fearon M, Castro E. *Trypanosoma cruzi* infection in North America and Spain: estimating the risk of transfusion transmission. [Abstract P-357]. *Vox Sanguinis* 2012; 103 (Suppl. 1):181.
210. **Stramer SL**, Carrick M, Linnen J, Muñoz-Jordán L, Hunsperger E, Foster GA, Boucher C, Miller D, Dickson S, Lanteri C, Bentsen C. Comparing the yield of dengue viremic blood donations using NS1 antigen (Ag) and nucleic acid testing (NAT). [Abstract P-369]. *Vox Sanguinis* 2012;103 (Suppl.1):185.
211. Añez G, Heisey DAR, Espina LM, **Stramer SL**, Rios M. Phylogenetic and time-scale analysis of dengue virus types 1 and 4 circulating in blood donors from Puerto Rico and Key West, Florida, during 2010 epidemics. [Abstract P-374]. *Vox Sanguinis* 2012;103 (Suppl.1):187.
212. Añez G, Grinev A, Winkelman V, **Stramer SL**, Rios M. Dynamics in evolution of West Nile Virus from human infections in the US after 2006. [Abstract P-375]. *Vox Sanguinis* 2012;103 (Suppl. 1):187.
213. **Stramer SL**, Notari EP, Townsend RL, Custer B, Kamel H, Busch MP, RY Dodd. No evidence of *trypanosoma cruzi* incidence in United States blood donors: A 4-year study. [Abstract 5D-S43-03]. *Vox Sanguinis* 2012;103(Suppl. 1):58.

214. Añez G, Heisey DA, Espina LM, **Stramer SL**, Rios M. Phylogenetic analysis of dengue virus types 1 and 4 circulating in blood donors from Puerto Rico and Key West, Florida, during 2010 epidemics. [Abstract S3-010A]. *Transfusion* 2012;52 (Suppl. 3S):14A.
215. Notari EP, Brodsky J, Steele WR, Dodd RY, **Stramer SL**. HTLV-I/II prevalence and incidence from 2009-2011 in a large, geographically diverse sample of US blood donors. [Abstract P2-030A]. *Transfusion* 2012;52 (Suppl. 3S):11A.
216. Moritz E, Winton C, Johnson ST, Townsend RL, Foster GA, Devine P, Molloy P, Brissette E, Berardi V, **Stramer SL**. Specificity of antibody and nucleic acid tests for detecting *Babesia microti* in repository of samples collected from assumed non-endemic US areas. [Abstract S60-030J]. *Transfusion* 2012;52 (Suppl. 3S):36A.
217. Steele WR, Hewitt EH, Kaldun AM, Krysztof DE, Dodd RY, **Stramer SL**. Donors deferred for self-reported Chagas disease history: does it reduce risk? [Abstract S61-030J]. *Transfusion* 2012;52 (Suppl. 3S):36-37A.
218. Gorlin JB, Devine P, Berardi V, Doeden K, Janzen MA, Brissette E, Molloy P, Weeks KE, Moritz E, **Stramer SL**. Investigational *Babesia microti* blood donation screening in a United States endemic region. [Abstract S62-30J]. *Transfusion* 2012;52 (Suppl. 3S):37A.
219. **Stramer SL**. Current perspectives in transfusion-transmitted infectious diseases: emerging and imported infections, including parasites. [Abstract 1D-H08-02]. *Vox Sanguinis* 2013;105 (Suppl. 1):8.
220. Leiby DA, Nguyen ML, Bhattacharyya T, Falconar AK, Miles MA, Townsend RL, **Stramer SL**. Preliminary investigations of a *Trypanosoma cruzi* lineage-specific serologic assay capable of identifying infected blood donors at greatest risk for transmitting infection. [Abstract 3C-S20-02]. *Vox Sanguinis* 2013;105 (Suppl. 1):39.
221. Moritz ED, Johnson ST, Winton CS, Tonnetti L, Townsend RL, Foster GA, Krysztof DE, Devine P, Molloy J, Brissette EM, Berardi VP, **Stramer SL**. Blood donor screening for *Babesia microti*: implications for blood safety. [Abstract 3C-S20-04]. *Vox Sanguinis* 2013;105 (Suppl. 1):39-40.
222. Rios M, Añez G, Heisey DA, Espina LM, **Stramer SL**. Molecular, virological and phylogenetic characterization of dengue virus types 1 and 4 infecting blood donors from Puerto Rico, 2012. [Abstract 4A-S32-05]. *Vox Sanguinis* 2013;105 (Suppl. 1):57-8.
223. **Stramer SL**, Boucher CB, Foster GA, Krysztof DE, Winton CS, Merced CL, Miller D, Dickson S, Brodsky JP, Muñoz-Jordán JL, Hunsperger A, Lanteri MC, Añez GJ, Heisey AR, Rois J, Corey E, Linnen JM. Investigational dengue testing yields high rates of RNA-positive donors in Puerto Rico. [Abstract P-376]. *Vox Sanguinis* 2013;105 (Suppl. 1):195.
224. Moritz E, Johnson ST, Winton C, Townsend RL, Tonnetti L, Foster GA, Brissette EM, Berardi VP, **Stramer SL**. Prospective investigational blood donation screening for *Babesia microti* (Bm). [Abstract P1]. *Transfusion* 2013;53 (Suppl. 2S):13A.
225. Grinev A, Chancey C, Añez G, Heisey DA, Volkova E, Winkelman V, Williamson PC, **Stramer SL**, Rios M. New genotype of west nile virus was found in the 2012 US epidemic season. [Abstract S26-020B]. *Transfusion* 2013;53 (Suppl. 2S):26A.
226. Grinev A, Heisey DA, Espina LM, **Stramer SL**, Rios M. Molecular, Virological, and Phylogenetic characterization of Dengue Virus Types 1 and 4 in Blood Donors from Puerto Rico, 2012-2013. [Abstract S28-020B]. *Transfusion* 2013;53 (Suppl. 2S):27A.
227. Allain J, Enjalbert F, Krysztof DE, Candotti D, **Stramer SL**. Comparison of seven Hepatitis B virus

Nucleic Acid Testing (NAT) assays in selected samples from American Blood Donors. [Abstract S29-020B]. *Transfusion* 2013;53 (Suppl. 2S):27A.

228. Townsend RL, Krysztof DE, Foster GA, Weixlmann BL, Muckenfuss SD, **Stramer SL**. *Trypanosoma cruzi* donor screening in the US; development of an algorithm for donor reentry. [Abstract S64-030J]. *Transfusion* 2013;53 (Suppl. 2S):43A.
229. Nguyen M, Townsend RL, **Stramer SL**, Bhattacharyya T, Falconar AK, Leiby DA. *Trypanosoma cruzi* lineage-specific serologic testing: convergence of parasitemia, high antibody titers, and blood donors at greatest risk for transmitting infection. [Abstract SP377]. *Transfusion* 2013;53 (Suppl. 2S):204A.
230. Townsend RL, Calhoun RD, Fialkow LB, Berardi VP, **Stramer SL**. Probable transfusion-transmission of anaplasma phagocytophilum (AP) by leukoreduced platelets. [Abstract SP380]. *Transfusion* 2013;53 (Suppl. 2S):205A.
231. Fucci MH, **Stramer SL**. Case Report: A repeat blood donor's testing and identification of potential public health risk. [Abstract SP390]. *Transfusion* 2013;53 (Suppl. 2S):209A.
232. **Stramer SL**, Foster GA, Brodsky JP, Muñoz-Jordan JL, Hunsperger E, Lanteri MC, Añez G, Rios M, Cory R. Investigation dengue testing yields high rates of ribonucleic acid (RNA)-positive donors in Puerto Rico. [Abstract SP409]. *Transfusion* 2013;53 (Suppl. 2S):216A.
233. Nelson DM, Notari EP, **Stramer SL**, Krysztof DE, Dodd RY, Kessler DA, Miller-Benson L, Shaz, Kaidarova Z, Custer B. Feasibility of constructing a multicenter blood donation database for surveillance purposes in the US. [Abstract A7-030G]. *Transfusion* 2013;53 (Suppl. 2S):223A.
234. Moritz E, Winton C, Townsend RL, Tonnetti L, Berardi VP, **Stramer SL**. Extended *Babesia microti* Investigational screening studies: implications for transfusion-transmitted babesiosis (TTB). [Abstract S25-020B]. *Transfusion* 2014;54 (Suppl. 2S):26A-27A.
235. Vahidnia F, **Stramer SL**, Kessler DA, Leparac GF, Krysztof DE, Dodd RY, Glynn S, Custer B. Motivations for donating and attitudes towards screening policies in donors with viral infection. [Abstract S49-030H]. *Transfusion* 2014;54 (Suppl. 2S):36A-37A.
236. Moritz E, **Stramer SL**. Risk factors identified in blood donors screening positive or inconclusive for *Babesia microti*. [Abstract SP379]. *Transfusion* 2014;54 (Suppl. 2S):207A-208A.
237. Custer B, Kessler D, Vahidnia F, Leparac GF, Krysztof DE, Shaz BH, Kamel H, Glynn S, Dodd RY, **Stramer SL**. Behavioral factors associated with HIV, HBV, HCV, and HTLV infections in US Blood Donors. [Abstract SP384]. *Transfusion* 2014;54 (Suppl. 2S):209A-210A.
238. Leiby DA, Hapip CA, Kenney JL, Mutebi J, Ahmed A, **Stramer SL**. Preliminary investigations of donor exposure to eastern equine encephalitis virus and implications for risk. [Abstract SP394]. *Transfusion* 2014;54(Suppl. 2S):214A.
239. **Stramer SL**, Dodd RY, Chiu CY. Advances in testing technology to ensure transfusion safety – NAT and beyond. *ISBT Science Series* 2015;10(Suppl 1):55-64.
240. Spencer BR, **Stramer SL**, Dodd RY, Kleinman SH, Hollinger B, Krysztof DE, Katz L. Survey to estimate donor loss to 14- or 28-day travel deferral for mitigation of CHIKV, DENV, and other acute infections. [Abstract P1-030A]. *Transfusion* 2015; 55(Suppl.3):3A.
241. Bres V, Ocampo D, Pekny K, Hanhan M, Gore SJ, Self D, Janssen A, Cory R, Ong E, **Stramer SL**, Linnen JM. Performance characteristics of a transcription-mediated amplification assay on fully automated system to detect dengue virus types 1-4 in blood donations. [Abstract SP308]. *Transfusion*



2015;55(Suppl. 3):182A.

242. Moritz E, **Stramer SL**. Antibody and DNA duration in asymptomatic blood donors who screen positive in investigational testing for *Babesia microti*. [Abstract SP330]. Transfusion 2015;55 (Suppl.3): 192A.
243. Spencer BR, Cable RG, Papallo C, Foster GA, Holley GC, Deisting B, Winton C, Krysztof D, **Stramer SL**. Male plateletpheresis donors are an unrecognized group with risk for iron depletion. [Abstract P4-030A]. Transfusion 2016; 56 (Suppl. S4):4A.
244. **Stramer SL**, Townsend RL, Notari EP, Foster GA, Brodsky JP, Herron RM, Dodd RY. Antochthonous Chagas transmission in the United States: Is one-time anti-*Trypanosoma cruzi* donor testing adequate? [Abstract S61-0301]. Transfusion 2016:56 (Suppl. S4):28A.
245. Tonnetti L, Laughhunn A, Thorp AM, Vasilyeva I, Stassinopoulos A, Dupuis K, **Stramer SL**. Inactivation of *Babesia microti* with Amustaline/GSH in red blood cells. [Abstract SP438]. Transfusion 2016:56(Suppl. S4):195A.
246. Tonnetti L, Thorp AM, Laughhunn A, Vasilyeva I, Stassinopoulos A, **Stramer SL**. Inactivation of *Babesia microti* with Amotosalen/UVA in platelet concentrates manufactured in 100% plasma. [Abstract SP439]. Transfusion 2016:56(Suppl. S4):196A.